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Sodium bicarbonate (NaHCO3) is an extracellular buffering agent and nutritional ergogenic aid 
that can improve high-intensity exercise performance. Based upon prior research, NaHCO3 
supplementation can improve markers of exercise metabolism, recovery and performance due 
to its ability to augment extracellular buffering capacity and delay exercise-induced fatigue. 
Nevertheless, gastrointestinal (GI) side-effects are widely reported following NaHCO3 
ingestion, which might deter athletes from using NaHCO3 or confound the benefits of 
supplementation. When combined with gastric acid, NaHCO3 produces excess carbon dioxide 
that can lead to various GI symptoms, including stomach cramps, bowel urgency and diarrhoea. 
Bypassing the stomach presents a novel strategy to prevent GI symptoms, which may be 
achieved using gastro-resistant capsules. Gastro-resistant NaHCO3 could therefore offer a 
convenient and practical strategy to reduce GI symptoms associated with NaHCO3 
supplementation, whilst improving exercise performance. Nevertheless, the efficacy of enteric-
coated NaHCO3 supplementation has yet to be investigated. The subsequent investigations 
were conducted to further explore the effect of gastro-resistant NaHCO3 supplementation on 
GI symptoms, acid-base responses and high-intensity exercise performance in recreationally 
trained and trained males. Given that delayed-release capsules are suggested to bypass the 
stomach and reduce GI symptoms caused by acidic-sensitive compounds (such as NaHCO3), 
this was investigated in Study 1. Compared with the solution, delayed-release NaHCO3 reduced 
the prevalence and severity of GI symptoms and slowed metabolic alkalosis, although the 
overall acid-base responses (e.g. peak blood [HCO3
–] and pH) were similar. Nevertheless, it 
was unclear whether these affects were related to encapsulation or the gastro-resistant 
properties of the capsule. Based on these findings, it could also be suggested that enteric-coated 
NaHCO3, which are more gastro-resistant than delayed-release capsules, could further reduce 
GI symptoms. Study 2 therefore investigated the effects of different gastro-resistant capsules 
VI 
 
(i.e. delayed-release and enteric-coated) compared with a standard capsule (i.e. gelatine) on GI 
symptoms and acid-base responses. Gastro-resistant capsules mitigated GI symptoms 
compared with the gelatine capsule, suggesting that bypassing the stomach is an efficacious 
strategy to reduce GI symptoms following NaHCO3 ingestion. Whilst enteric-coated NaHCO3 
resulted in the fewest (and less severe) GI symptoms, acid-base responses were blunted with 
this ingestion form. Study 3 therefore investigated whether enteric-coated NaHCO3 could still 
improve high-intensity exercise performance. Enteric-coated NaHCO3 improved exercise 
performance during a 4 km cycling time trial in trained males, although the magnitude of effect 
was lower than with gelatine capsules. Collectively, these studies demonstrate that bypassing 
the stomach is an efficacious strategy to reduce GI symptoms with NaHCO3 supplementation, 
which can be achieved using gastro-resistant capsules. gastro-resistant NaHCO3 can therefore 
be used to mitigate GI symptoms, although these findings also suggest they should not replace 
standard ingestion forms in those who can tolerate them. Based on the available evidence, 
practical recommendations are provided for athletes which will develop as further research is 
conducted in this area. With this knowledge, further explorations into different gastro-resistant 















Publications arising from the thesis: .................................................................................... IV 
Abstract ............................................................................................................................... V 
Chapter 1: General Introduction ............................................................................................ 1 
1.1 Introduction to research area ............................................................................................ 2 
1.2 Structure of thesis ............................................................................................................ 3 
1.3 Aims ............................................................................................................................... 3 
Chapter 2: Literature Review................................................................................................. 5 
2.1 Determinants of exercise fatigue and performance ........................................................... 6 
2.2 Origins of fatigue ............................................................................................................ 7 
2.2.1 Metabolic acidosis and fatigue ...................................................................................... 8 
2.3 Acid-base balance ......................................................................................................... 10 
2.4 Body buffer systems ...................................................................................................... 11 
2.4.1 Bicarbonate buffer system .......................................................................................... 12 
2.4.2 Respiratory and renal compensation ........................................................................... 13 
2.5 Sodium bicarbonate ....................................................................................................... 13 
2.5.1 Mechanism of action .................................................................................................. 14 
2.5.2 Dose ........................................................................................................................... 15 
2.5.3 Ingestion timing ......................................................................................................... 16 
2.5.4 Ingestion form ............................................................................................................ 17 
2.5.5 Effects on high-intensity exercise performance ........................................................... 18 
2.6 Gastrointestinal side-effects ........................................................................................... 19 
2.6.1 Implications of gastrointestinal symptoms .................................................................. 21 
VIII 
 
2.6.2 Strategies to reduce gastrointestinal symptoms ........................................................... 21 
2.6.3 Gastro-resistant formulations ...................................................................................... 22 
2.7 Summary ....................................................................................................................... 23 
Chapter 3: General Methods ................................................................................................ 24 
3.1 Ethical considerations .................................................................................................... 25 
3.2 Participants.................................................................................................................... 26 
3.3 Experimental procedures ............................................................................................... 26 
3.4 Determination of peak oxygen uptake ............................................................................ 27 
3.5 Gas analysis .................................................................................................................. 28 
3.6 Heart rate ...................................................................................................................... 28 
3.7 Blood sampling ............................................................................................................. 29 
3.8 Perceptual measures ...................................................................................................... 29 
Chapter 4: The Effects of Delayed-Release Sodium Bicarbonate Supplementation on 
Gastrointestinal Symptoms and Markers of Acid-Base Balance ........................................... 31 
4.1 Introduction ................................................................................................................... 32 
4.2 Methods ........................................................................................................................ 34 
4.2.1 Participants ................................................................................................................. 34 
4.2.2 Study overview........................................................................................................... 34 
4.2.3 Baseline assessment.................................................................................................... 35 
4.2.4 Experimental trials ..................................................................................................... 36 
4.2.5 Statistical analyses ...................................................................................................... 36 
4.3 Results .......................................................................................................................... 37 
4.3.1 Gastrointestinal symptoms .......................................................................................... 37 
4.3.2 Acid-base balance....................................................................................................... 40 
IX 
 
4.4 Discussion ..................................................................................................................... 44 
4.5 Conclusion .................................................................................................................... 47 
Chapter 5: Enteric-Coated Sodium Bicarbonate Attenuates Gastrointestinal Side-Effects and 
Alters Acid-Base Responses ................................................................................................ 48 
5.1 Introduction ................................................................................................................... 49 
5.2 Methods ........................................................................................................................ 50 
5.2.1 Participants ................................................................................................................. 50 
5.2.2 Experimental overview ............................................................................................... 50 
5.2.3 Assessment of acid-base balance ................................................................................ 51 
5.2.4 Gastrointestinal symptoms .......................................................................................... 52 
5.2.5 Statistical analyses ...................................................................................................... 52 
5.3 Results .......................................................................................................................... 53 
5.3.1 Gastrointestinal symptoms .......................................................................................... 53 
5.3.2 Acid-base responses ................................................................................................... 57 
5.4 Discussion ..................................................................................................................... 60 
5.5 Conclusions ................................................................................................................... 62 
Chapter 6: The Effects of Enteric-Coated NaHCO3 Supplementation on High-Intensity 
Exercise Performance in Trained Cyclists ........................................................................... 64 
6.1 Introduction ................................................................................................................... 65 
6.2 Methods ........................................................................................................................ 66 
6.2.1 Participants ................................................................................................................. 66 
6.2.2 Experimental design ................................................................................................... 67 
6.2.3 Preliminary testing ..................................................................................................... 68 
6.2.4 Experimental testing ................................................................................................... 69 
6.2.5 Time trials .................................................................................................................. 69 
X 
 
6.2.6 Physiological and perceptual measures ....................................................................... 70 
6.2.7 Statistical analyses ...................................................................................................... 70 
6.3 Results .......................................................................................................................... 71 
6.3.1 Exercise performance ................................................................................................. 71 
6.3.2 Acid–base balance ...................................................................................................... 74 
6.3.3 Electrolyte responses .................................................................................................. 75 
6.3.4 Physiological and perceptual responses ...................................................................... 77 
6.3.5 Gastrointestinal symptoms .......................................................................................... 79 
6.4. Discussion .................................................................................................................... 80 
6.5 Conclusions ................................................................................................................... 84 
Chapter 7: Synthesis of findings .......................................................................................... 86 
7.1 Gastrointestinal symptoms............................................................................................. 88 
7.1.1 Prevalence of gastrointestinal symptoms with sodium bicarbonate supplementation ... 89 
7.2 Implications of gastro-resistant sodium bicarbonate ....................................................... 90 
7.2.1 Gastrointestinal symptoms .......................................................................................... 90 
7.2.2 Ingestion timing ......................................................................................................... 92 
7.2.3 Bicarbonate kinetics and other acid–base responses .................................................... 94 
7.2.4 Efficacy of enteric-coated sodium bicarbonate to improve exercise performance ........ 95 
7.3 Limitations .................................................................................................................... 96 
7.4 Future directions............................................................................................................ 97 
7.5 Conclusions and implications ........................................................................................ 98 















Chapter 1: General Introduction 
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1.1 Introduction to research area 
Human exercise performance that relies upon anaerobic metabolism has limited capacity 
(MacLaren, 1989; Baker et al. 2010). Despite the conscious will of the athlete to drive 
mechanical work rate, performance inevitably falls and eventually ceases (MacLaren, 1989). 
This concept of fatigue has intrigued scientists for decades (Mosso, 1915, Di Giulio, Daniele 
and Tipton, 2006) and attempts to underpin the mechanisms of exercise-induced fatigue and 
delay its deleterious effects on exercise performance has been the focus of considerable 
research. To date, there is currently substantial evidence (Maughan et al. 2018) that both 
exercise training and nutritional intervention can delay exercise-induced fatigue. 
Intense exercise provides a significant challenge to maintain physiological homeostasis 
in humans. Exercise demanding high rates of adenosine triphosphate (ATP) relies upon 
anaerobic glycolysis, although its capacity is limited, at least in part, due to the accumulation 
of hydrogen ions. While considerable debate remains as to the mechanisms of fatigue during 
exercise, increases in hydrogen ion concentration ([H+]) are regarded as contributory. 
Exogenous buffering systems have evolved in humans to remove excessive metabolites and 
thus maintain [H+] within extremely narrow limits. In the absence of this mechanism, 
deviations to homeostasis would lead to catastrophic failure of the entire organism. In the 
context of sport, metabolic acidosis is considered at least partly attributable to impaired skeletal 
muscle contraction and reductions in exercise performance. 
Multiple attempts to delay the deleterious effects of fatigue on performance have been 
made, both in relation to exercise training and nutritional strategies. Research studies indicate 
that exercise training can induce significant improvements in exogenous buffering capacity, 
that can translate to improved exercise performance (Laursen and Jenkins, 2002). Of the 
nutritional strategies employed, acute sodium bicarbonate (NaHCO3) loading has been found 
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to have a profound effect on exercise performance. In a meta-analysis, NaHCO3 
supplementation was associated with moderate (1.7 ± 2.0%) improvements during a single 1-
minute sprint, increasing by ~ 0.5 ± 0.5% for a larger dose or five additional sprint bouts. 
While the ergogenic efficacy of NaHCO3 ingestion is well established during intense 
(anaerobic) exercise, oral administration is associated with gastrointestinal (GI) side-effects 
(Cameron et al. 2010, Kahle et al. 2013, Saunders et al. 2014a), including stomach bloating 
and diarrhoea. Gastro-resistant compounds can reduce GI side-effects associated with the oral 
administration of acid-sensitive compounds, although this has yet to be applied in the context 
of sport. 
1.2 Structure of thesis 
The overall purpose of this thesis is to explore the role of gastro-resistant NaHCO3 on acid-
base balance, GI symptoms and exercise performance. Firstly, a review of the current literature 
will examine the factors modulating the effect of NaHCO3 supplementation on exercise 
performance and the potential application of gastro-resistant ingestion forms (Chapter 2). The 
subsequent chapter will detail the general methods that will be employed to answer the 
respective research questions, including the procedures that will remain consistent across all 
studies that compose this thesis (Chapter 3). Next, a series of experimental studies will be 
conducted that will address the research aims (Chapters 4, 5 and 6). Finally, the overarching 
conclusions will be discussed in relation to existing bodies of work and practical 
recommendations will be provided for athletes and coaches (Chapter 7). 
1.3 Aims 
Research has been presented which indicates that acute NaHCO3 loading can improve exercise 
performance, although this can also result in GI side-effects. The neutralisation of gastric acid 
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is shown to increase carbon dioxide production, which in turn, can result in GI symptoms 
including stomach bloating, vomiting and diarrhoea. Consequently, this can reduce the 
performance-enhancing effects of NaHCO3 supplementation and in some cases, may even be 
ergolytic. Gastro-resistant NaHCO3 may therefore present a novel strategy to mitigate GI 
symptoms whilst improving exercise performance. However, there is no empirical evidence to 
suggest that ergogenic doses of gastro-resistant NaHCO3 can reduce GI symptoms and 
subsequently improve exercise performance (~ 300 mg·kg–1 body mass). This thesis will 
therefore address the following research aims. 
1. Determine the prevalence and severity of GI symptoms with NaHCO3 supplementation 
(addressed in Studies 1, 2 and 3) 
2. Explore the role of gastro-resistant capsules on GI symptoms and acid-base responses 
(addressed in Studies 1 and 2) 
3. Investigate the efficacy of gastro-resistant NaHCO3 to improve high-intensity exercise 



















2.1 Determinants of exercise fatigue and performance 
Human exercise performance is determined by numerous physiological, psychological and 
biomechanical factors (Joyner and Coyle, 2008) that are relative to the specific demands of the 
task. Although physiological exercise capacity does not determine exercise performance per 
se, its superiority is considered to enhance the potential for better exercise performance. For 
almost a century, Exercise Physiologists have studied the physiological determinants of human 
performance, particularly in relation to fatigue and its origins. In a series of studies conducted 
by Hill and colleagues in the early 1920’s (Hill and Lupton, 1923, Hill, Long and Lupton, 
1924a, 1924b, 1924c), the concept of maximal oxygen consumption (V̇O2max) was introduced, 
proposing that there was an inter-individual upper limit to oxygen uptake which was limited 
by the cardiorespiratory systems ability to transport oxygen (O2) to skeletal muscle. The 
authors suggested that a high V̇O2max was a significant determinant of endurance performance 
and was regulated by cardiac output and an elevated arteriovenous O2 difference. Elite 
endurance athletes have indeed reported superior V̇O2max values due to substantial adaptations 
to aerobic exercise training (Costill et al. 1976). Later research (Bassett and Howley, 2000) 
suggested that the ability to sustain higher work rates for longer durations is associated with 
superior O2 efficiency and exercise performance. Indeed, maintaining aerobic metabolism as 
the predominant energy supplier was found to be associated with a delay in fatigue, and 
performance could be sustained for prolonged periods. When work rate exceeded that which 
could be supplied by aerobic metabolism, anaerobic pathways became predominant and the 
individuals were deemed to have reached their anaerobic threshold (Joyner and Coyle, 2008). 
Anaerobic threshold is suggested to represent the work rate at which a dynamic equilibrium is 
reached between metabolite production and removal (Billat et al. 2003), beyond which 
substantial deviations to bodily homeostasis occur, and thus exercise performance falls 
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dramatically. Enhanced removal of these metabolites or a greater tolerance to their 
accumulation is as suggested, essential to delay the effects on performance. 
The origins and purpose of fatigue are controversial and intensely debated topics, of 
which a consensus has yet to be reached. Scientists have proposed both peripheral and central 
origins (Gandevia, 2001, St Clair Gibson and Noakes, 2004) of fatigue. Peripheral origins of 
fatigue suggest that fatigue occurs within, or distal to the neuromuscular junction, thereby 
limiting external work that can be mechanically performed. Central mechanisms of fatigue 
propose that work rate and fatigue are regulated by the brain through central motor output. 
Sensory information obtained through feedforward mechanisms is used to adjust central motor 
output to avoid catastrophic deviations to homeostasis that would otherwise be induced by 
exercise (St Clair Gibson and Noakes, 2004). Two central mechanisms have been proposed, 
including the central governor model, a largely subconscious phenomena, and the 
psychobiological model, proposing that conscious perception of effort adjusts central motor 
output (St Clair Gibson and Noakes, 2004, Marcora and Staiano, 2010). While evidence exists 
to support these models of fatigue, it is currently accepted that both central and peripheral 
factors contribute to the onset of fatigue (Thomas et al. 2014). 
 
2.2 Origins of fatigue 
Exercise-induced fatigue is commonly defined as the impaired ability to produce muscular 
force during exercise, often accompanied with an increased perception of effort (Gandevia, 
2001, Enoka and Stuart, 1985). Fatigue can be attributed to various processes along the motor 
pathway that are broadly split into central and peripheral origins (Amann, 2011). Central 
fatigue suggests that declines in muscle force reside within the central nervous system (i.e. 
brain and spinal cord), including changes in neurotransmitter activity, motor cortical output 
and muscle efferent and afferent feedback (Gandevia, 2001). Furthermore, the central nervous 
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system preserves the development of peripheral fatigue, primarily through increases in 
ventilation, cardiac output and muscle blood flow during exercise (Amann and Calbet, 2008). 
In contrast, peripheral fatigue attributes the declines in muscle force to processes across the 
neuromuscular junction and sarcolemma (Gandevia, 2001). This includes a lack of excitation-
contraction coupling and metabolite accumulation (e.g. H+) which perturb acid-base balance 
(Allen et al., 2008). Fatigue is therefore the result of contributions from both central and 
peripheral processes, which are largely determined by the exercise task (e.g. intensity). Fatigue 
that is induced during high-intensity, short-duration exercise typically has a substantial 
peripheral component, whereby the contributions from the central nervous system are relatively 
low (Schillings et al. 2003). Nevertheless, central fatigue becomes predominant as the exercise 
duration increases or during submaximal but prolonged exercise intensities (Smith et al. 2007, 
Sogaard et al. 2006). The mechanisms to explain how this occurs, however, are complex, 
controversial and currently widely debated. 
  
2.2.1 Metabolic acidosis and fatigue 
The fuels used in anaerobic exercise (e.g. 100 m sprint) differs from those used in aerobic 
exercise (e.g. half marathon) and is largely determined by the intensity and duration of exercise 
(Baker et al. 2010). During high-intensity exercise, the demand for ATP is high, and therefore 
requires a high rate of ATP production from fuels other than stored ATP and phosphocreatine 
(Gastin, 2001). 
 Through the process of glycolysis, one glucose molecule is broken down to form two 
pyruvate molecules and H+ (MacLaren and Morton, 2012). Given the high oxygen and energy 
(i.e. ATP) demand during high-intensity exercise, pyruvate remains within the cytoplasm and 
converts to lactate – a process termed anaerobic glycolysis. This series of ten enzyme-catalysed 




Figure 2.1. Breakdown of glucose to form pyruvate, lactate and H+ during anaerobic glycolysis 
(adapted from MacLaren and Morton, 2012). 
 
Muscle fatigue is thought to be at least partly the result of a decrease in muscle pH due to the 
accumulation of H+ during anaerobic glycolysis. Whilst the mechanisms responsible for the 
onset of muscle fatigue across are equivocal (Fitts, 2016; Westerblad, 2016), reductions in 
muscle pH are associated with simultaneous declines in muscle excitability (Cairns & 
Lindinger, 2008), contractility (Spriet et al. 1985) and exercise performance (Raymer et al. 
2004). Nevertheless, these causes of muscular fatigue are currently contested, with research 
suggesting a negligible role of pH on force generation and recovery (Westerblad, 2016). It is 
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well established enzymes have an optimal pH and that acidosis can result in reduced glycolytic 
enzyme activity (MacLaren et al. 1989), suggesting at least some role of acidosis on muscle 
fatigue. This is further supported by the observation that inducing acidosis decreases high-
intensity exercise performance (Correia-Oliveira et al. 2017), whereas alkalosis can improve it 
(Carr et al. 2011c). 
 
2.3 Acid-base balance 
Acid-base balance governs the acidity or alkalinity of a solution, which is largely determined 
by [H+] and is more often expressed as the logarithm termed potential hydrogen (pH) in 
Equation 1. 
 
(1) pH = –log10 [H
+]. 
 
Given that pH is the negative logarithm of [H+], there is inverse relationship between 
blood [H+] and pH. Elevations in [H+] thereby result in a lower pH, a state commonly termed 
acidosis. Given that small changes in [H+] disturb protein and membrane function, bodily pH 
is regulated within very narrow limits. Despite disagreement as to normal pH reference values, 
blood pH is considered to fluctuate between 7.35 and 7.45 AU to facilitate metabolic and 
physiological processes (Berend, 2013). Biochemical sources of H+ include intermediary and 
end-products of metabolism such as glycolysis, specially under anaerobic conditions (i.e. 
anaerobic glycolysis). Exercise therefore provides a substantial endogenous source of H+ that 
is relative to the energetic demands of the activity. Consequently, humans have developed 
intricate mechanisms to maintain pH within the various bodily compartments, including that 




2.4 Body buffer systems 
Buffer systems primarily exist to regulate acid-base balance, and work to maintain dynamic 
equilibrium between an un-dissociated weak acid (HA) and its conjugate base (A−), as depicted 
in Equation 2. 
 
(2) HA = [H+] + A− 
 
Should [H+] rise, they are combined with the weak base to form additional weak acid 
therefore lowering [H+]. Conversely, should there be a fall in [H+], more may be liberated from 
the weak acid. Both reactions operate to return [H+] and therefore pH, to within normal limits. 
Metabolic acidosis is the result of substantial elevations in [H+] and occurs when blood pH falls 
below ~7.35 AU, whereas metabolic alkalosis occurs when [H+] decreases and blood pH 
exceeds ~7.45 AU. In both cases, an effective system is required to mediate acid-base balance 
and avoid deleterious effects on the human body. Three basic mechanisms exist to maintain 
pH homeostasis in man, including physicochemical buffering and respiratory and renal 
compensation. 
Extracellular buffering occurs through transporting protons (e.g. H+) out of the muscle 
and into the blood. Across the muscle membrane, monocarboxylate transporters 1- and 4 are 
responsible for maintaining muscle pH (Bishop et al. 2006) through the translocation of lactate 
and H+ by the lactate/H+ transporter. Given that monocarboxylate transporter 4 is expressed in 
high quantities in glycolytic type IIb muscle fibres and those with low mitochondrial density 
(Bishop et al. 2006), the bicarbonate buffer system plays a significant role in extracellular 
buffering (Poupin et al., 2012). 
12 
 
2.4.1 Bicarbonate buffer system 
Physicochemical buffering works instantaneously to attenuate fluctuations in pH. Elevations 
in pH stimulates proteins, haemoglobin, phosphates or bicarbonate to undergo chemical 
reactions that prompt their disposal (Atherton, 2009, Poupin et al. 2012). Of the 
physicochemical mechanisms, the bicarbonate buffer system is fundamental to maintaining 
acid-base balance, accounting for 86% of total buffering capacity in extracellular space, with 
protein and haemoglobin responsible for the remaining 14% (Poupin et al. 2012). Within 
intracellular space, bicarbonate is accountable for 34% of overall buffer capacity, whereas 
proteins and phosphates have a superior role and are responsible for a combined 66% of total 
buffer capacity (Atherton, 2009, Poupin et al. 2012). 
Bicarbonate buffering regulates blood pH by combining H+ with HCO3
− to form 
carbonic acid (H2CO3), which in turn, dissociates to CO2 and water H2O. This reversible 
process is catalysed by the enzyme carbonic anhydrase and is expressed in Equation 3. 
 
Carbonic anhydrase 




The abovementioned reaction occurs until a state of dynamic equilibrium is reached, in 
that elevations in either H+ or CO2 drives the reaction in the opposing direction. In this way, 
rises in CO2 partial pressure stimulates H2CO3 formation which then dissociates to H
+ and 
HCO3
−, thus increasing acidity within the solution. Similarly, elevations in [H+] stimulates 
H2CO3 formation, which dissociates to CO2 and H2O thus inducing an alkalising effect. 
Multidirectional movement of this reaction however is limited, due to the finite availability of 
[HCO3
−]. Depleting HCO3
− induces substantial elevations in [H+] which reflects the upper limit 
of the bicarbonate buffer system. Bicarbonate buffering can therefore only reduce the 
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magnitude of pH changes alone. Consequently, the respiratory and renal systems compensate 
by either removing excess CO2 or releasing additional HCO3
− to preserve pH homeostasis, 
respectively. 
 
2.4.2 Respiratory and renal compensation 
Similar to bicarbonate buffering, respiratory compensation is readily available and acts to 
reduce arterial CO2 concentrations. Respiratory compensation therefore lessens dependence on 
bicarbonate buffering to maintain blood pH. This is achieved through a combination of 
increasing expired CO2 and a rise in pulmonary ventilation (Atherton, 2009). Given that 
deoxygenated haemoglobin (venous blood) has greater CO2 buffering capacity than 
oxygenated haemoglobin (arterial blood), this promotes venous CO2 uptake and increases 
VCO2 (Rubana and Aulik, 1989). Furthermore, increased PaCO2 detected by peripheral and 
central chemoreceptors stimulates the vasomotor centre of the medulla to increase respiratory 
rate and tidal volume (Mitchell et al. 1963). These processes are fundamental during all forms 
of exercise, when there are substantial elevations in [H+] and CO2 (Guyton, 1976). Renal 
compensation can provide a significant contribution to pH regulation through replenishing 
bicarbonate stores. Exercise-induced disturbances to acid-base balance are not directly 
regulated by the kidneys as this system typically functions over several days (Atherton, 2009). 
 
2.5 Sodium bicarbonate 
Investigations into skeletal muscle fatigue and exercise performance spans almost a century. 
Early work (Dennig et al. 1931, Dill, Edwards and Talbot, 1932) speculated that inducing a 
state of alkalosis could enhance exercise performance, although research on the ergogenic 
potential of buffering agents was not prominent until the mid-seventies (Jones et al. 1977, 
14 
 
Sutton, Jones and Toews, 1981, McCartney, Heigenhauser and Jones, 1983, Kowalchuk, 
Heigenhauser and Jones, 1984). 
The ingestion of NaHCO3 is now a well-established nutritional strategy that can 
enhance exercise performance that relies heavily on anaerobic glycolysis (McNaughton et al. 
2016). This is currently regarded as high-intensity exercise bouts sustained for 1-10 min 
(Matson and Tran, 1993), and sports involving repeated sprint bouts over longer durations (30-
60 minutes). As an extracellular buffering agent, NaHCO3 helps to maintain pH homeostasis 
by reinforcing endogenous physicochemical buffering, namely that of the bicarbonate buffer 
system (Atherton, 2009). Ingestion of NaHCO3 causes a transient increase in circulating HCO3
– 
and results in a corresponding increase in blood pH (Costill et al. 1983). By inducing this state 
of metabolic alkalosis, NaHCO3 helps to maintain intramuscular pH during strenuous exercise, 
where there is a significant increase in the production of H+. Given that H+ can impair skeletal 
muscle contraction (Fabiato and Fabiato, 1978) and reduce energy turnover through glycolytic 
pathways (Sahlin et al. 1975), accumulation of H+ is associated with performance decrements 
(Fitts, 2016). Generally, it is accepted that elevated levels of circulating [HCO3
–] enhance 
efflux of H+ from the active muscle (Ren et al. 1988; Bangsbo et al. 1995) by the lactate-proton 
transporters, monocarboxylate transporters 1 and 4 (Mainwood and Worsley-Brown, 1975). 
However, alternative mechanisms have been proposed including enhanced excitation-
contraction coupling and strong ion regulation (Siegler et al. 2016). Fundamentally, there is a 
delay in the onset of fatigue, which is associated with performance improvements. 
 
2.5.1 Mechanism of action 
The psycho-physical basis of fatigue is controversial at least, and the direct mechanisms in 
which NaHCO3 might evoke an ergogenic effect, are therefore unclear. In addition, empirical 
research has focused on the impact of NaHCO3 on performance outcomes, with less aiming to 
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elucidate its potential mechanism. While multiple mechanisms have been postulated, NaHCO3 
is repeatedly cited to attenuate intramuscular acidity which contributes to skeletal muscle 
fatigue (Sahlin, 1992, Fitts, 1994, Knuth et al. 2006, Messonnier et al. 2007, Kent-Braun, Fitts 
and Christie, 2012). Anaerobic glycolysis yields H+ as a metabolite, which accumulates in 
skeletal muscle if production exceeds removal, and reduces intramuscular pH. Muscle biopsies 
taken after high-intensity exercise to exhaustion reveal intramuscular pH falls to ~6.5 AU from 
~7.1 AU at rest (Ahlborg et al. 1972, Costill et al. 1983, 1984), indicating substantial changes 
to acid-base balance. One mechanism to explain how intramuscular acidosis contributes to 
muscular fatigue suggests that competition between H+ and calcium ions (Ca2+) for troponin 
binding sites impairs skeletal muscle contraction (Donaldson, Hermansen and Bolles, 1978, 
Fabiato and Fabiato, 1978). Other mechanisms include the inhibition of both phosphocreatine 
resynthesis (Sahlin, Harris and Hultman, 1975), and glycolytic enzymes such as glycogen 
phosphorylase and phosphofructokinase (Sutton, Jones and Toews, 1981). Ingestion of 
NaHCO3 causes a transient but significant rise in blood [HCO3
−], which is accompanied by an 
increase of [HCO3
−] in the extracellular environment. In turn, this steepens the 
intracellular/extracellular [H+] gradient and stimulates the lactate/H+ co-transporters 
(Hermansen and Osnes, 1972, Mainwood and Worsley-Brown, 1975, Mainwood and Cechetto, 
1980, Roth, 1991). Enhanced bicarbonate buffering and efflux of H+ towards extracellular 
compartments reduces intramuscular pH, thus attenuating impairments in skeletal muscle 
contraction and associated exercise performance. 
 
2.5.2 Dose 
In order to attain sufficient increases in blood [HCO3
–], large boluses of NaHCO3 must be 
orally ingested and are typically prescribed relative to an individual’s body mass. While 200 to 
300 mg·kg–1 body mass are the most commonly ingested doses of NaHCO3, the efficacy of 
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doses ranging from 100 to 500 mg·kg–1 body mass has been examined across the literature 
(McNaughton 1992a, Stannard et al. 2016). Since the early work of McNaughton (1992), a 
dose-response relationship is considered to exist between NaHCO3 supplementation and 
performance, with no further improvements occurring beyond 300 mg·kg–1 body mass.  
Elevations in blood [HCO3
–] therefore increase relative to the ingested dose, and absolute 
increases exceeding 6 mmol∙L-1 are frequently observed for doses of 300 mg·kg–1 body mass 
(Heibel et al. 2018). Increases of this magnitude (i.e. ≥ 6 mmol∙L-1) have been suggested to 
represent a threshold whereby an ergogenic effect is deemed ‘almost certain’ (Matson and 
Tran, 1993, Carr et al. 2011b). In some cases, a dose of both 200 and 300 mg·kg–1 body mass 
has demonstrated a comparable performance enhancing effect (Heibel et al. 2016; Stannard et 
al. 2016). 
 
2.5.3 Ingestion timing 
Recently, the timing of ingestion has been recognised to impact the likelihood of observing an 
ergogenic effect (Heibel et al. 2016; Miller et al. 2016). Typically, NaHCO3 is administered 60 
to 90 min prior to exercise (Higgins et al. 2013; Christensen et al. 2014), although recent 
investigations have further questioned this ingestion strategy. Indeed, current findings propose 
that when exercise coincides with peak alkalosis, a highly reproducible ergogenic response is 
observed (Gough et al. 2018). Contrary to prior research (McKenzie et al. 1986), lower doses 
(200 mg·kg–1 body mass) have produced equivalent performance improvements to higher doses 
(300 mg·kg–1 body mass), although this is variable between indidivuals (Gough et al. 2018). 
However, numerous studies (Jones et al. 2006; Gough at el., 2017b; Sparks et al. 2017) have 
observed a large degree of inter-individual variability in the time to reach peak alkalosis when 
examined up to 3 h post-ingestion. In relation to [HCO3
–] availability, both the time to reach 
peak [HCO3
–] and absolute change demonstrate extreme variability between individuals, 
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although both appear to increase with higher doses (Jones et al. 2016). Across the literature, 
studies have reported that time-to-peak bicarbonate can occur between 10 to 180 min post-
ingestion (Miller et al. 2016; Jones et al. 2016) highlighting the magnitude of the variability. 
Similarly, absolute change in bicarbonate varies between individuals and may account for 
equivocal findings regarding ergogenic effects. While significant variability exists between 
individuals, both time-to-peak bicarbonate and pH demonstrate a high degree of reliability 
(Gough et al. 2017). Given that the bicarbonate response is deemed more reproducible than 
pH, current research suggests that ingestion timing should be based on the timing of peak blood 
[HCO3
–]. Whilst further research is required to conclude whether exercise performed at peak 
[HCO3
–] may indeed optimise NaHCO3 supplementation, there is some evidence to support 
this ingestion strategy. 
 
2.5.4 Ingestion form 
Two different NaHCO3 dosage forms have been used across the literature, including solutions 
and gelatine capsules, although only one study has made a direct comparison of their effect on 
acid-base balance and GI-related side-effects (Carr et al. 2011c). Solutions are the most 
common way of administering NaHCO3, whereby the white crystalline powder is dissolved in 
water. In some instances, flavoured cordial is added to the solution to enhance palatability and 
provide a taste-matched placebo. Whilst little attention has been given to how ingestion form 
may alter the ergogenic response to NaHCO3 supplementation, both ingestion forms (solution 
and gelatine capsules) have demonstrated performance-enhancing effects. In studies by 
Bellinger (Bellinger et al. 2012) and Driller (Driller et al. 2012), mean power output improved 
by a similar degree (~3.1%) when NaHCO3 was ingested with 10 ml·kg
–1 body mass water 90 
minutes prior to 4-minute maximal cycling. Similarly, when the equivalent dose was ingested 
in gelatine capsules with comparable quantities of water, TTE improved by 2.7% in a study by 
18 
 
Van Mondtfoort (Van Montfoort et al. 2004), demonstrating that both forms of administration 
can enhance performance. Interestingly, Driller (Driller et al. 2012) reported mild bloating and 
nausea in 38% participants, whereas Van Mondtfoort (Van Montfoort et al. 2004) reported no 
such side-effects, although ingestion with gelatine capsules is still associated with GI distress 
(Sale et al. 2011, Saunders et al. 2014a). 
 
2.5.5 Effects on high-intensity exercise performance 
Of the extracellular buffering agents available, NaHCO3 is currently regarded as the most 
effective, with various narrative reviews (Heibel et al. 2018; McNaughton et al. 2016) and 
meta-analyses (Carr et al. 2011c) to support this claim. While a significant body of research 
suggests that NaHCO3 enhances exercise performance, not all studies have reported an 
ergogenic effect following supplementation (Saunders et al. 2014a; Webster et al. 1993; Kupcis 
et al. 2012). Equivocal findings may be attributable, at least in part, to the exercise protocol 
employed in the respective study. As an extracellular buffering agent, the efficacy of NaHCO3 
is observed during exercise that induces a performance-limiting degree of metabolic acidosis. 
Hence, an ergogenic effect should only be observed during exercise that liberates energy (i.e. 
ATP) under anaerobic conditions. Given that high-intensity, short-duration exercise up to ~ 30 
s is not primarily limited by reductions in muscular pH, NaHCO3 has not been found to be 
beneficial during single exercise bouts of this duration (McNaughton, 1992a). Similarly, 
endurance-based and steady-state exercise does not induce substantial perturbations to acid-
base homeostasis. While some studies suggest that NaHCO3 may improve endurance-based 
performances (McNaughton, Dalton and Palmer, 1999), most have reported no benefit 
(Northgraves et al. 2014; Stephens et al. 2002; Freis et al. 2017). The efficacy of NaHCO3 is 
most notable during single-bouts of high-intensity exercise lasting ~ 1-10 min (Deb et al. 2017, 
2018; McNaughton et al. 2016), or during repeated bouts of short-duration (4-90 s) exercise 
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(Price, Moss and Rance, 2003; Bishop  et al. 2004; Bishop and Claudius, 2005; Krustrup et al. 
2015; Miller et al. 2016), where there is a significant degree of muscular acidosis (Hermansen 
and Osnes, 1972; Belfry et al. 2012). Indeed, consistent improvements in performance have 
been noted during repeated bouts of high-intensity exercise, while intermittent high-intensity 
sports have also reported similar ergogenic effects (Artioli et al. 2007; Lindh et al. 2008; Siegler 
and Hirscher, 2010; Tan et al. 2010). In a comprehensive meta-analysis, a moderate (~ 1.7%) 
performance-enhancing effect was observed for a single 1-min bout of high-intensity exercise, 
which increased by 0.5% for five additional bouts (Carr, Hopkins and Gore, 2011). However, 
mean improvements reported with NaHCO3 are highly variable between studies, and multiple 
factors have been suggested to modulate the individual response (Heibel et al. 2018). Factors 
such as dose, ingestion timing and training status may all influence individual responses to 
NaHCO3 supplementation, and increase the variability observed between subjects. 
Furthermore, there is evidence to suggest that there is a large degree of within-subject 
variability in the ergogenic response with NaHCO3, which may be affected by adverse side-
effects and blood responses (Saunders et al. 2014b). Prior meta-analyses may have therefore 
underestimated the effect size of NaHCO3, and caution should be taken when interpreting 
pooled data to assess the efficacy of this supplement. 
 
2.6 Gastrointestinal side-effects 
Acute GI distress is a frequently reported side-effect following the oral ingestion of NaHCO3 
(Cameron et al. 2010, Kahle et al. 2013, Saunders et al. 2014a) and may arguably be a major 
determinant of its use among athletes. While various aetiologies have been proposed, the 
neutralisation of stomach acid is considered the main contributing factor. Indeed, when 
NaHCO3 enters the stomach, the [HCO3
–] dissociates and neutralises the highly acidic stomach 




– and hydrochloric acid produces substantial volumes of CO2 in the stomach. Figure 2.2 
illustrates the reaction between HCO3
– and hydrochloric acid present in the stomach which 
produces CO2.  Consequently, this can result in abdominal pain, nausea and diarrhoea 
(Breitkreutz et al. 2007), although symptoms can vary between individuals. 
 
 
Figure 2.2. Reaction between bicarbonate (HCO3
–) and hydrochloric acid (HCl) producing 
CO2. Adapted from Kalantar-Zadah et al. (2019).  
 
Ergogenic doses (300 mg∙kg–1 body mass) of NaHCO3 typically results in sodium intakes that 
exceed dietary reference values (> 2300 mg∙day–1). In turn, this can create osmotic fluctuations 
in the intestinal lumen leading to GI symptoms including diarrhoea (Gisolfi, 1990). As such, 
GI symptoms may be at least partly due to the high dose of sodium ingested. Nevertheless, the 
neutralisation of gastric acid is considered the main contributing factor, given that GI side-
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effects are far more prevalent and severe following NaHCO3 ingestion compared with sodium 
chloride (Gough et al. 2018). 
 
2.6.1 Implications of gastrointestinal symptoms 
Given that side-effects vary between individuals, this may account for the large intra-individual 
differences observed in performance. In a study by Saunders (Saunders et al. 2014a), an 
ergogenic effect was only detected when subjects who experienced GI distress, including 
moderate to severe stomach cramps and diarrhoea, were removed from statistical analyses. The 
remaining subjects reported a 4.7% improvement in total work done during a supramaximal 
(110% peak power) cycle bout to exhaustion. Another explanation for large intra-individual 
differences in performance may be related to symptom tolerance. Research trials have reported 
that some individuals can undergo performance enhancing effects of acute NaHCO3 loading 
despite symptoms of GI distress (McNaughton, 1992, Miller et al. 2016), whereas others cannot 
(Cameron et al. 2010, Saunders et al. 2014a). Discrepancies between studies may relate to 
symptom severity, however some studies did not provide sufficient detail relating to side-
effects and direct comparisons cannot be made. In practice however, GI distress still presents 
an issue for athletes, and multiple strategies to reduce its negative implications have been 
researched (McNaughton and Thompson, 2001; Mueller et al. 2013; Sale et al. 2011, Saunders 
et al. 2014a, Saunders et al. 2014b). 
 
2.6.2 Strategies to reduce gastrointestinal symptoms 
Multiple dosing strategies have been investigated to minimise the incidence and severity of GI 
symptoms, including chronic (McNaughton and Thompson, 2001), multi-day (Mueller et al. 
2013) and split-dose (Sale et al. 2011, Saunders et al. 2014a, Saunders et al. 2014b) 
administration. Chronic and multi-day administration provides excessive quantities of sodium 
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which present other side-effects, whereas split dosing protocols may still induce GI distress 
(Sale et al. 2011, Saunders et al. 2014a, Saunders et al. 2014b). Given that larger doses appear 
to increase the incidence or worsen the severity of GI distress (Wilkes, Gledhill and Smyth, 
1983, Goldfinch, McNaughton and Davies, 1988), particularly those exceeding 300 mg·kg–1 
body mass as proposed by McNaughton (McNaughton, 1992), smaller doses may minimise the 
risk of side-effects. In contrast, incidences of stomach cramp, bowel urgency and diarrhoea 
have still been reported using a dose ≤ 300 mg·kg–1 body mass (Miller et al. 2016), highlighting 
the need for using an individualised approach. Athletes are therefore encouraged to pilot 
NaHCO3 supplementation pre-season or during training to establish their tolerance to various 
doses. 
 
2.6.3 Gastro-resistant formulations 
Cellulose is a polysaccharide consisting of a linear chain of glucose (Figure 2.3) and is present 
in plant cell walls (Barbosa, Conway and Merchant, 2017). Given that cellulose is resistant to 
acidic pH and becomes soluble in less acidic conditions, cellulose-based capsules have been 








Using baths to simulate the gastric and intestinal environments of humans, gastro-resistant 
capsules resist degradation at high acidity (pH 1-2 AU) and typically degrade in the more 
alkaline environment (pH 6-7 AU). Preventing capsule degradation can therefore postpone the 
release of NaHCO3, which in turn, prevents gastric acid from being neutralised and reduces 
symptoms such as nausea and vomiting (Barbosa, Conway and Merchant, 2017). Whereas 
enteric-coated capsules are suggested to bypass the stomach entirely, the gastro-resistant 
functionality of delayed-release capsules is variable. Furthermore, it is generally accepted that 
enteric-coated capsules breakdown further into the GI tract and are considered more gastro-
resistant compared with delayed-release capsules. 
 
2.7 Summary 
In summary, GI side-effects appear to be associated with NaHCO3 supplementation, 
particularly following the oral ingestion of ergogenic doses. While several mechanisms have 
been proposed, the neutralisation of gastric acid is thought to be a contributing factor. 
Nevertheless, little research has attempted to reduce the prevalence and severity of GI 
symptoms, and athletes currently have limited practical options to minimise these adverse 
effects. However, there is a growing research interest in nutritional strategies that may optimise 
NaHCO3 supplementation using novel ingestion forms. Fundamentally, there is a need to 
resolve the challenges inherent with using this nutritional supplement, focusing on alternatives 

























The purpose of this chapter is to outline the procedures that will remain consistent across all 
studies that compose this thesis. This will include a description, justification and, were 
applicable, the test-retest reliability data. Experimental design and methods that are specific to 
each study will be described in the relevant chapters. 
 
3.1 Ethical considerations 
Ethical approval was granted for all studies in this thesis from the Department of Sport and 
Physical Activity Research Ethics Committee and the University Research Ethics Sub-
Committee at Edge Hill University. Blood sampling was carried out in accordance to the local 
Human Tissue Authority license regulations and no blood samples were stored. Participation 
in the study was entirely voluntary and no remuneration was provided. All participants were 
given a Participant Information Sheet that clearly outlined study commitments, experimental 
procedures and any associated risks. Participants were given at least one week to read the 
document and fully consider the requirements of participation. Furthermore, study protocols 
were explained in full and questions were answered prior to gaining written informed consent 
to participate. Participants had the right to withdraw from the study during experimentation 
and up until the point of individual data collection being completed. No participants requested 
to withdraw their consent during any study. All testing was carried out at the Physiology 
laboratory in the Department of Sport and Physical Activity, Edge Hill University. 
All participants were required to complete a medical screening questionnaire before 
taking part in any study to minimise the risk of adverse events during exercise. Participants 
were also asked to inform the researcher if there was a change in health status throughout 
experimental testing. Participants also completed a pre-exercise screening questionnaire before 
each exercise trial (Chapter 6). This also involved measuring heart rate and blood pressure. 





measured using an automated sphygmomanometer. Inclusion criteria was systolic blood 
pressure ≤ 140 mmHg, diastolic blood pressure ≤ 90 mmHg and heart rate < 90 beats·min–1 
(and regular on palpation). If any measure exceeded this criteria exercise was not be permitted 
and the participant was advised to seek medical advice before being reconsidered. 
 
3.2 Participants 
Healthy adult males between the ages of 18-60 years were recruited to participate in each study. 
None of the participants had a history of GI disease and none were under pharmacological 
intervention during any study. Exclusion criteria included those with hypertension, renal 
impairment or following a salt-restricted diet. Specific participant characteristics are described 
in each study chapter. Training status was classified in accordance with the criteria outlined by 
De Pauw et al. (2013). In Chapters 4 and 5, participants are described as recreationally trained 
due to participating in regular exercise (> 4 h·week–1) and having a peak oxygen uptake 
(V̇O2peak) between 45.0-54.9 ml∙kg–1∙min–1. In Chapter 6, the participants are described as 
trained cyclists based on meeting the following criteria; V̇O2peak 55.0-64.9 ml∙kg–1∙min–1, 
training frequency ≥ 3 d·week–1 and cycling distance > 60 km·week–1. 
 
3.3 Experimental procedures 
Before each experimental trial, participants undertook several standardised procedures to limit 
the confounding effects of nutrition, hydration status and day-to-day physiological variation. 
These procedures were confirmed verbally on arrival to the laboratory during each visit. 
Experimental trials for example, were conducted at the same time of day (0900 h) to minimise 
the physiological effects of circadian rhythms (Reilly, 1990). Participants were asked to 





caffeine consumption for 12 h, and strenuous exercise 24 h before each laboratory visit 
(Weststrate et al. 1990, Westerterp-Plantenga et al. 2006). Water intake was encouraged in the 
24 h preceding experimental testing sessions to ensure euhydration. A normal habitual diet was 
maintained, although participants attended the laboratory following an overnight fast (~ 12 h). 
All experimental trials took place under ambient laboratory conditions (room temperature = 
18-20 °C, humidity = 40-50%). 
 
3.4 Determination of peak oxygen uptake 
During the experimental studies, V̇O2peak was determined using an incremental exercise test to 
volitional exhaustion on an electromagnetically-braked cycle ergometer (Lode Excalibur Sport, 
Groningen, The Netherlands). After a 5 min warm-up at 70 watts (W), the workload increased 
by 30 W·min–1 (1 W every 2 s) until volitional exhaustion. Participants selected a preferred 
cadence (70–120 rev∙min–1) to maintain throughout, with volitional exhaustion defined as an 
inability to maintain > 60% of this cadence for > 5 s despite strong verbal encouragement. 
Breath-by-breath gases were used to measure oxygen uptake (V̇O2), carbon dioxide production 
(V̇CO2), minute ventilation (V̇E) and the respiratory exchange ratio (RER). Heart rate (Polar®, 
Kempele, Finland) and rating of perceived exertion (RPE) were also recorded each minute 
(Borg, 1973). The following criterion were used to confirm that V̇O2peak had been reached: (i) 
heart rate within 10 beats∙min–1 of age-predicted maximum; (ii) respiratory exchange ratio > 
1.10 arbitrary units (AU); (iii) RPE > 18/20 AU (Midgley et al. 2007). Data were then averaged 
into 10 s bins with V̇O2peak defined as the highest 10 s average of oxygen uptake (V̇O2) obtained 






3.5 Gas analysis 
Breath-by-breath gases were measured continuously during exercise using an online gas 
analysis system (Oxycon Pro™, Jaeger, Germany). The Oxycon Pro™ has previously been 
reported to be both valid and reliable, as it possesses a relatively low (< 7%) coefficient of 
variation (CV) for all parameters (Carter and Jeukendrup, 2002). Prior to each use, the gas 
analysis system was switched on after a warm-up period (1 h) was allowed, before being 
calibrated in accordance with manufacturer instructions. This involved using an automated 
calibration procedure using a calibration gas (16.25% oxygen, 4.13% carbon dioxide and 
79.62% nitrogen), which was repeated until the current data for gain, offset and delay time 
were within very low (≤1%). Furthermore, volume calibration was conducted using a 3 L 
syringe (Hans Rudolph, USA), whereby six complete pumps of the syringe were performed 
until the difference between the current and previous volume calibration was very low (≤1%). 
As data were collected continuously during exercise, participants were required to wear a face 
mask (Hans Rudolph, USA). 
 
3.6 Heart rate 
Heart rate will be recorded continuously during exercise using a telemetric monitoring system 
(Polar®, Kempele, Finland). This required participants to wear a heart rate transmitter belt 
across their chest in line with the xiphoid process and with the electrodes moistened to enhance 
signal amplitude. Heart rate was recorded at several time points during each trial, which are 






3.7 Blood sampling 
Fingertip capillary blood samples (95 μL) were taken at various time points, which are 
described in each study chapter. All samples were taken using a disposable lancet (AccuCheck 
Safe-T-Pro, Indianapolis, USA) using an aseptic technique and collected in heparin-coated 
glass capillary tubes (Radiometer Medical Ltd, Denmark). Samples were analysed immediately 
(Radiometer ABL800 BASIC, Denmark) for acid-base balance and electrolyte content, 
including blood [HCO3
–] and pH, as well as blood sodium ([Na+]), potassium ([K+]) and 
chloride ([Cl–]) ion concentrations. The ABL800 BASIC radiometer has been shown good to 
excellent criterion validity compared with other commercially available devices (Stadlbauer et 
al. 2011). Furthermore, good to excellent test-retest reliability has been shown for blood 
[HCO3
–] (r = 0.76-0.94; CV < 5%) and pH (r = 0.62-0.71; CV < 5%) using a 300 mg·kg–1 body 
mass dose (Gough et al. 2017b). The ABL800 BASIC radiometer in the Physiology laboratory 
at Edge Hill University has also demonstrated excellent test-retest reliability (CV < 5%) in a 
small pilot study. During exercise trials, further 5 μL blood samples were collected to measure 
blood lactate ion concentration ([La–]) at various intervals. Samples were measured using a 
portable analysing device (Lactate Pro 2, LT-1730, Arkray, Japan) that has demonstrated good 
reliability (Pyne et al. 2000). Blood bicarbonate kinetics were used to determine characteristics 
of the ingestion forms, including lag time (Tlag), peak blood [HCO3
–] (Cmax), change in Cmax (∆ 
Cmax), time-to-reach Cmax (Tmax) and area under the curve (AUC). Bicarbonate Tlag was defined 
as the point at which blood [HCO3
–] increased beyond normal daily fluctuation. 
 
3.8 Perceptual measures 
Throughout the exercise trials, perceived exertion and perceived fatigue were measured at 





perceived exertion (RPE-L) and RPE were recorded using a 6–20 scale (Borg, 1982), whereas 
perceived ratings of fatigue (ROF) were recorded on a 10-point Likert scale (Micklewright et 
al. 2017). Symptoms of GI distress were recorded using an adapted GI symptom questionnaire 
(Carr et al. 2011) including nausea, flatulence, stomach cramping, belching, stomach ache, 
bowel urgency, diarrhoea, vomiting, and stomach bloating. Symptoms were self-measured on 
a 10 cm visual analogue scale where “0 = No symptom” and “10 = Severe symptom” (Miller 
et al. 2016). Symptom terminology was explained to participants before the experimental trials 
















Chapter 4: The Effects of Delayed-Release Sodium Bicarbonate Supplementation on 








Acute bicarbonate loading with NaHCO3 is a well-established nutritional ergogenic strategy. 
Supplementation can improve short-duration (1-10 min), high-intensity exercise performance 
(McNaughton et al. 2016), with various meta-analyses confirming its efficacy (Matson and 
Tran, 1993, Carr, Hopkins and Gore, 2011, Christensen et al. 2017). As an extracellular 
buffering agent, NaHCO3 enhances endogenous bicarbonate buffering capacity by inducing 
significant, albeit transient, elevations in extracellular bicarbonate. Consequently, this 
enhances efflux of H+ from skeletal muscle, therefore delaying muscle fatigue and positively 
affecting numerous performance variables, such as power output (Bellinger et al. 2012) and 
time to exhaustion (Higgins, James and Price, 2013). Whilst it remains unclear whether 
minimal increases are required to achieve these benefits, substantial changes (~6 mmol∙L–1) in 
[HCO3
–] may improve the likelihood of performance enhancing effects (Matson and Tran, 
1993, Carr, Hopkins and Gore, 2011, Bellinger et al. 2012, Higgins, James and Price, 2013, 
Christensen et al. 2017, Heibel et al. 2018). Given that bicarbonate is lost in the neutralisation 
of gastric acid (Turnberg et al. 1970), large oral doses (200-300 mg∙kg–1 body mass) are 
required to induce meaningful elevations in the blood. 
Acute GI distress is a known side-effect of ingesting large amounts of NaHCO3 (Burke 
and Pyne, 2007), particularly when administered as a solution (Carr et al. 2011). Ergogenic 
effects have still been observed in those reporting GI distress (McNaughton et al. 2016, Miller 
et al. 2016), however there is evidence to suggest that GI distress may be ergolytic for some 
individuals (Kahle et al. 2013, Saunders et al. 2014a, McNaughton et al. 2016, Barbosa, 
Conway and Merchant, 2017). Furthermore, some authors have suggested that GI distress may 
deter individuals from using NaHCO3 regardless of its potential ergogenic benefits (Heibel et 
al. 2018). Although the impact of GI distress on performance remains ambiguous, symptoms, 





coaches. Whilst split-dose protocols can help to alleviate GI symptoms (Sale et al. 2011, 
Saunders et al. 2014a, Saunders et al. 2014b), there is little consensus regarding how this 
protocol should be implemented, and the evidence relating to exercise performance is scarce. 
Furthermore, most research studies have adopted an acute loading protocol which is ingested 
60-90 min prior to exercise (Renfree, 2007, Price and Simons, 2010, Carr et al. 2011, Siegler 
et al. 2012). Developing novel acute loading strategies which can alleviate GI symptoms may 
therefore represent a more practical ingestion strategy for athletes during training and/or 
competition. 
Gastro-resistant capsules can resist gastric degradation and reduce GI symptoms 
provoked by acid sensitive compounds, such as NaHCO3 (Farias de Oliveira, Saunders and 
Artioli, 2018). Hydroxypropyl methylcellulose, contained in delayed-release capsules, can 
resist degradation in acidic environments (pH ~1-2 arbitrary units (AU)), and therefore 
provides gastro-resistant properties.  Instead, degradation occurs in the duodenum were the pH 
is far more alkaline (pH ~ 6-7 AU) and absorption can take place rapidly. Since GI distress is 
partly attributable to degradation in the stomach (Turnberg et al. 1970), it has been suggested 
that gastro-resistant capsules may alleviate symptoms that are typical with NaHCO3 ingestion 
(Farias de Oliveira, Saunders and Artioli, 2018). Given that less bicarbonate is lost in the 
stomach, it has also been suggested that smaller doses may produce comparable acid-base 
changes to larger doses (Farias de Oliveira, Saunders and Artioli, 2018). In contrast, as the time 
available for absorption is reduced with gastro-resistant formulations (Barbosa, Conway and 
Merchant, 2017), this may reduce bicarbonate bioavailability when administered in this form. 
No study to date has examined the use of delayed-release NaHCO3 on markers of GI distress, 
nor on bicarbonate bioavailability and subsequent blood acid-base responses. Reducing GI 
distress following NaHCO3 ingestion may enhance use by athletes, particularly among those 





The aim of this study was, therefore, to investigate whether delayed-release NaHCO3 
could mitigate GI distress compared with a solution using an acute loading protocol, as well as 
compare the acid-base responses following supplementation. 
4.2 Methods 
4.2.1 Participants 
Twelve trained (according to DePauw et al. 2013) healthy males (age 26 ± 5 y, V̇O2peak 58.9 ± 
10.9 ml∙kg–1∙min–1, height 1.8 ± 0.1 m, body mass 82.3 ± 11.1 kg, fat-free mass 72.3 ± 10.0 kg) 
were recruited for the study. The study was approved by the University Research Ethics 
Committee before the participants gave written informed consent to take part in the study. 
Inclusion in the study required that participants had performed regular (≥ 3 d∙week–1) physical 
exercise for at least two years. Exclusion criteria included ingestion of any buffering agents < 
6 months prior to commencing the study, and those with hypertension or on a sodium-restricted 
diet. 
4.2.2 Study overview 
Before taking part in the experimental trials, each participant underwent a baseline assessment 
over two laboratory visits separated by at least 48 h to establish (i) body composition and 
V̇O2peak and (ii) fluctuations in blood analytes ([HCO3
–] and pH) under normal conditions. 
Fluctuations in blood analytes and GI symptoms under normal conditions were used as a 
control measure throughout. In the experimental trials, all participants underwent two 
conditions; 300 mg∙kg–1 body mass NaHCO3 administered as either a solution or encased in 
delayed-release capsules. Experimental trials were administered in a block randomised 
crossover design that were counterbalanced (Latin-square) in order of administration, and took 





2004). Participants were required to abstain from alcohol or caffeine-containing beverages for 
12 h and strenuous exercise 24 h before each laboratory visit. All sessions took place under 
standardised laboratory conditions (temperature = 21–22 °C, relative humidity = 50–55%, 
barometric pressure = 756–759 mmHg) and were conducted at 0900 h to account for circadian 
rhythms (Reilly, 1990). 
4.2.3 Baseline assessment 
Participants arrived at the laboratory on both occasions after an overnight fast (~12 h) and 
euhydrated. On one visit, semi-nude body mass and fat-free mass were assessed using whole-
body air displacement plethysmography (BOD POD®, COSMED, Italy). Participants then 
performed an incremental exercise test to volitional exhaustion on an electromagnetically-
braked cycle ergometer (Excalibur Sport, Lode, Netherlands). After a standardised 5 min 
warm-up at a power output of 70 W, the cycling protocol commenced at 75 W for 1 min and 
workload increased by 1 W every 2 s (30 W·min–1) until volitional exhaustion. This was 
determined by the inability of the participant to sustain their respective self-selected cadence 
for > 5 s despite feedback and strong verbal encouragement. On a separate visit, fingertip 
capillary blood samples were obtained using an aseptic technique after the participants were 
quietly seated for 20 min. Blood samples were drawn every 20 min over 180 min, with 10 min 
sampling between 80 and 140 min to accurately capture peak values (Gough et al. 2017b). 
Blood samples were collected in 100 μL heparin-coated glass capillary tubes (Radiometer 
Medical Ltd, Denmark) and immediately analysed using a blood gas analyser (ABL800 
BASIC, Radiometer Medical Ltd., Denmark). At the same time points, GI symptoms were 
recorded using a 9-item questionnaire, including nausea, flatulence, stomach cramping, 
belching, stomach ache, bowel urgency, diarrhoea, vomiting and stomach bloating (Carr et al. 





symptom” and “10, severe symptom”, as previously described (Miller et al. 2016). Participants 
remained seated throughout, although toilet breaks were permitted. No food was consumed 
during the experimental trials and water was permitted ad libitum, with volumes replicated in 
the subsequent experimental session. 
4.2.4 Experimental trials 
Solutions were prepared in 400 ml of natural mineral water (Evian®, France) and mixed with 
50 ml of sugar-free blackcurrant flavoured squash (Robinsons®, UK) and refrigerated (~1 h) to 
enhance palatability (Miller et al. 2016) . For the delayed-release condition, size 00 capsules 
(DRcaps™, Capsugel®, France) were prefilled with NaHCO3 using a capsule filling device 
(Capsule Connection LLC, USA), while doses were checked for accuracy using digital 
laboratory scales (Fisher, OHAUS™). Participants were instructed to ingest either the solution 
or delayed-release capsules with an equal volume (400 ml) of water within 10 min, while the 
stopwatch commenced parallel with the start of ingestion (Jones et al. 2016, Gough et al. 
2017b). All experimental trials were conducted under the same conditions as the control trial, 
with blood analytes and GI symptoms measured as previously described. 
4.2.5 Statistical analyses 
Prospective statistical power analysis was conducted a priori to determine that twelve 
participants were required, with alpha and beta set at 0.05 and 0.20, respectively. Data were 
assessed for normality using standard graphical methods prior to analyses (Grafen and Hails, 
2002). Two-way analysis of variance (ANOVA) with repeated measures (condition × time) 
was used to establish significant main effects for blood analytes ([HCO3
–], pH and BE) and GI 
symptom scores. Condition consisted of two levels (solution and delayed-release capsules) 





min). Effect sizes were calculated using partial eta-squared (p2) for ANOVA and were 
interpreted according to Cohen (Cohen, 1988) as follows: trivial <0.20; small 0.20-0.49; 
moderate 0.50-0.79 and large  0.80. Sphericity was assessed using Mauchly’s test throughout. 
Where appropriate, corrections for violations of sphericity (Greenhouse-Geisser) and multiple 
comparisons of differences within a factor (Bonferroni) were made (Atkinson, 2002). Mean 
HCO3
– kinetic variables and highest GI symptoms score between conditions were analysed by 
paired samples t-test. Descriptive data are presented as either mean ± standard deviation (SD) 
unless stated otherwise. The α-level of statistical significance was set at P < 0.05, and exact P-
values are given in the text and tables. Values for P of “0.000” given by the statistical package 
were corrected to “< 0.0005” (Kinnear and Gray, 1995). Data were analysed using the 
Statistical Package for the Social Sciences (SPSS®) for Windows® (IBM, Chicago, IL, USA), 
version 25. 
4.3 Results 
4.3.1 Gastrointestinal symptoms 
Frequency 
No GI symptoms were reported pre-ingestion, nor at any time point in the control condition. 
All participants (n = 12) experienced at least one GI symptom following either solution or 
capsule ingestion (Table 4.1). Stomach bloating was the most prevalent GI symptom in both 
experimental trials, although the prevalence was lower with delayed-release capsules (58%) 
than with the solution (100%). Overall, fewer GI symptoms (mean difference −45.1%) were 
reported with delayed-release capsules than with a solution (Figure 4.1). Furthermore, each GI 








Table 4.1. The most severe individual GI symptom reported during any trial. Symptom 
scores are displayed in parenthesis and are expressed as arbitrary units (AU). 
Participant Control Solution Delayed-release 
1 No symptom (0.0) Stomach cramp (3.5) Stomach bloating (3.0) 
2 No symptom (0.0) Bowl urgency (7.0) Stomach bloating (3.0) 
3 No symptom (0.0) Nausea (6.0) Nausea (2.0) 
4 No symptom (0.0) Diarrhoea (10.0) Stomach bloating (7.0) 
5 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (7.0) 
6 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (5.5) 
7 No symptom (0.0) Bowl urgency (6.0) Bowl urgency (5.0) 
8 No symptom (0.0) Bowl urgency (10.0) Bowl urgency (2.0) 
9 No symptom (0.0) Diarrhoea (10.0) Belching (3.0) 
10 No symptom (0.0) Diarrhoea (10.0) Belching (3.0) 
11 No symptom (0.0) Stomach ache (3.0) Belching (3.0) 
12 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (7.0) 
Mean (SD) 0.0 ± 0.0 AU 8.0 ± 2.7 AU 4.2 ± 2.0 AU 
 
Severity 
Symptom severity increased in the solution (P < 0.0005) and delayed-release (P = 0.017) 
conditions beyond those shown with the control. There was a significant effect of ingestion 





delayed-release capsules than with the solution (P = 0.001; Figure 4.1). There was no effect of 
time (F2.85, 31.36 = 2.89, P = 0.053, p2 = 0.21) and no significant condition × time interaction 
was found (F3.22, 35.39 = 1.87, P = 0.148, p2 = 0.15). The most severe GI symptom reported 
with delayed-release capsules (4.2 ± 2.0 AU) was significantly lower (P = 0.002) than with the 
solution (8.0 ± 2.7 AU). 
 
Figure 4.1. Incidence (A) and mean (± SD) severity (B) of GI symptoms. *Denotes significant 







Figure 4.2. Frequency of each GI symptom reported by all participants (n = 12). Values 
represent the number of participants that reported each symptom. 
4.3.2 Acid-base balance 
Bicarbonate 
Ingestion form had no significant effect on blood [HCO3
–] (F1.00, 11.00 = 0.71, P > 0.05, p2 = 
0.061) up to 180 min post-ingestion. There was a significant effect of time (F2.38, 26.23 = 101.74, 
P < 0.0005, p2 = 0.90); blood [HCO3–] increased from the previous time point for 60 min 
post-ingestion (P < 0.05), with no significant change up to 180 min post-ingestion (P > 0.005, 





P < 0.0005, p2 = 0.60). Blood [HCO3–] were significantly higher with the solution at 20 (P = 
0.008), 40 (P = 0.001) and 60 min (P = 0.011) than with the delayed-release capsules, and 
significantly lower at 130 (P = 0.021), 140 (P = 0.019) and 160 min (P = 0.047). 
 
 
Figure 4.3. Mean (± 95% confidence interval [CI]) blood [HCO3
–]. *Denotes significant 
difference between solution and delayed-release capsules (P < 0.05). 
 
Mean bicarbonate kinetic variables are displayed in Table 4.2. More participants reached a 5 
mmol∙L–1 (solution: n = 10; delayed-release: n = 11) and 6 mmol∙L–1 (solution: n = 8; delayed-
release: n = 9) increase in blood [HCO3








Figure 4.4. Individual changes in blood [HCO3




Ingestion form had no significant effect on pH (F1.00, 11.00 = 2.88, P = 0.188, p2 = 0.21) up to 
180 min post-ingestion. There was a significant effect of time (F4.42, 48.60 = 43.74, P < 0.0005, 
p2 = 0.80); blood pH increased markedly for 60 min (P < 0.05) post-ingestion, until a decrease 
occurred from the previous time point at 70 min (P < 0.0005) and continued to decrease up to 
180 min (P < 0.05) post-ingestion (Figure 4.5). A significant interaction was found between 
condition and time for pH (F4.88, 53.67 = 6.42, P < 0.0005, p2 = 0.37). Blood pH was 
significantly higher with the solution at 40 min (P = 0.009) than with the delayed-release 






Figure 4.5. Mean (± 95% CI) blood pH responses. *Denotes significant difference between 
solution and delayed-release capsules (P < 0.05). 
 
Blood pH peaked much later with the delayed release capsules (solution = 72 ± 26 min; 
delayed-release = 125 ± 28 min; P = 0.001) than with the solution, although absolute changes 
were comparable between conditions (solution = 0.08 ± 0.02 AU; delayed-release = 0.08 ± 









Table 4.2. Mean (± SD) bicarbonate kinetics in the solution and delayed-release conditions, 
together with the statistical significance of the difference. 
Variable Solution Delayed-release t-test P value 
Tlag (min) 20 ± 0* 32 ± 10 * -3.92 0.002 
Tmax (min) 72 ± 18** 120 ± 29** -5.35 <0.0005 
Cmax (mmol∙L
-1) 31.2 ± 1.1 31.8 ± 1.3 -1.66 0.125 
∆ Cmax (mmol∙L
-1) 6.4 ± 1.3 6.5 ± 1.1 -0.46 0.658 
AUC (mmol∙min/L) 5278 ± 174 5286 ± 198 -0.13 0.899 
Note: Asterix denotes significant difference between conditons (*P < 0.05; **P < 0.0005). 
Tlag, time to commence change in blood bicarbonate ion concentration; Tmax, time to reach 
peak blood bicarbonate ion concentration; Cmax, peak blood bicarbonate ion concentration; ∆ 




This is the first study to investigate the effects of gastro-resistant capsules on GI distress, 
bicarbonate bioavailability and subsequent acid-base responses following NaHCO3 ingestion. 
The main finding was that delayed-release NaHCO3 mitigated GI distress. Fewer GI symptoms 
were reported with the delayed-release capsules, and the overall severity was reduced when 
compared to the solution; a finding that has been suggested in the relevant literature (Farias de 
Oliveira, Saunders and Artioli, 2018). Gastrointestinal symptoms were negated with the 





following NaHCO3 supplementation (Table 4.1). Given that GI symptoms may be ergolytic 
(McNaughton, 1992, Kahle et al. 2013, Saunders et al. 2014a), delayed-release NaHCO3 may 
be more ergogenic in those who experience GI distress with the solution. Furthermore, since 
GI distress may deter some individuals from using NaHCO3 as an ergogenic aid (Carr et al. 
2011, Heibel et al. 2018), delayed-release NaHCO3 would appear to be a more favourable 
option for athletes and coaches. 
While necessary to achieve erogenicity (Jones et al. 2016), large boluses (200-300 
mg∙kg–1 body mass) of NaHCO3 can induce significant GI symptoms. In the current study, 
there was a high incidence of GI distress with the solution, which is in agreement with some 
authors (Kahle et al. 2013) but not others (Van Montfoort et al. 2004, Carr et al. 2011). On 
entering the stomach, NaHCO3 dissociates to sodium and [HCO3
–], the latter of which produces 
carbon dioxide during the neutralisation of gastric acid (Turnberg et al. 1970). Consequently, 
carbon dioxide tension increases exponentially with exposure and is associated with symptoms, 
such as belching, nausea and stomach ache. Delayed-release capsules, partly formulated with 
an enteric barrier, display gastro-resistant properties and can minimise disintegration in the 
stomach. Mitigating GI symptoms may indeed have implications for performance. Previous 
research indicates that symptoms can inhibit high-intensity cycling performance (Saunders et 
al. 2014a), while others have reported improvements irrespectively (McNaughton, 1992). Since 
numerous participants have withdrawn from studies due to GI distress (Gough et al. 2017a), 
previous research may have underestimated the ergolytic effect of such symptoms. Studies that 
have attempted to mitigate GI symptoms following NaHCO3 ingestion have used alternative 
dosing strategies. Gelatine capsules co-ingested with a small high-carbohydrate (1.5 g∙kg–1 
body mass) meal is currently regarded as the formulation least likely to induce GI symptoms 
following NaHCO3 ingestion (Carr et al. 2011). In the current study, delayed-release capsules 





on acid-base changes. Nevertheless, co-ingestion with a small high-carbohydrate meal may 
have further reduced GI symptoms and warrants further investigation. Furthermore, while 
comparison with a solution was chosen based on its frequency of use within the literature, this 
may not be the case in the practice and is thus a limitation to the study. Further research should 
therefore look to assess potential differences in GI and acid-base responses following NaHCO3 
supplementation using different capsules. 
In relation to bioavailability, both ingestion forms provided adequate sources of [HCO3
–
] and displayed similar kinetics. Increases in [HCO3
–] were comparable, with both forms 
exceeding the 6 mmol∙L–1 threshold suggested to enhance ergogenicity (Carr, Hopkins and 
Gore, 2011). Interestingly, some participants displayed enhanced bicarbonate availability (≥ 1 
mmol∙L–1) with delayed-release capsules (Figure 4.4), while only one participant was found to 
have enhanced bicarbonate availability of this magnitude with the solution. Similarly, more 
participants achieved a 5 to 6 mmol∙L–1 increase in [HCO3
–] with the delayed-release capsules 
than with the solution. These results would be explained by the gastric bypass model proposed 
by Oliveira et al (Farias de Oliveira, Saunders and Artioli, 2018), which includes the effect of 
gastric transit time and HCO3
– loss associated with neutralisation. As suggested by these 
authors, reducing HCO3
– neutralisation in the stomach increases bioavailability when NaHCO3 
is administered orally. Since changes of ~ 1 mmol∙L₋1 in blood [HCO3
–]  can positively affect 
performance (McNaughton, 1992), delayed-release NaHCO3 may be more ergogenic. In 
contrast to the solution, [HCO3
–] absorption did not commence immediately following capsule 
ingestion, suggesting that the delayed-release capsules were effective (Marzorati et al. 2015, 
Barbosa, Conway and Merchant, 2017). This result indicates that the capsules achieved 
disintegration in the intestine, which had the effect of lengthening (+ 48 min) the time to reach 
peak [HCO3
–]. Blood [HCO3
–] peaked at ~ 120 min post-ingestion with the delayed-release 





2017b) but not all (Jones et al. 2016). Similar to previous studies (Renfree, 2007, Siegler et al. 
2010, 2012), there was a high degree of individual variability in the time to reach peak [HCO3
–
], although this was greater with the capsules. When deciding an appropriate ingestion form, it 
is therefore advisable that athletes continue to monitor individual concentration-time profiles 
following NaHCO3 supplementation. 
Metabolic alkalosis was induced earlier with the solution (~ 40 min) than with delayed-
release capsules (~ 60 min), although this state was maintained for longer (+ 30 min) when 
ingested in the delayed-release form. Exercise performance timed with peak alkalosis may 
enhance the ergogenicity of NaHCO3 supplementation (Gough et al. 2017a, Heibel et al. 2018), 
therefore it is reasonable to consider that delayed-release may provide a larger ergogenic 
window. In a competitive setting, this may be more favourable since it is difficult to time 
exercise performance peak alkalosis due to variable factors, such as sports fixtures. In the 
current study, time to reach peak pH was much later with delayed-release NaHCO3 than with 
the solution. In a practical setting, delayed-release NaHCO3 would have to be ingested sooner 
than a solution to elicit similar acid-base changes (i.e. 90-120 min before exercise). 
4.5 Conclusion 
In summary, delayed-release NaHCO3 mitigates GI symptoms compared with a solution, 
which may be more appropriate for athletes who report symptoms post-ingestion. Given that 
blood [HCO3
–] and pH peaked much later with delayed-release NaHCO3, this would have to 
be ingested earlier (i.e. 90-120 min before exercise) than with a solution to induce comparable 
acid-base changes. The current study supports the gastric bypass model, which can be used as 
















Chapter 5: Enteric-Coated Sodium Bicarbonate Attenuates Gastrointestinal Side-






Acute GI disturbances are problematic following NaHCO3 supplementation (Burke and Pyne, 
2007, Cameron et al. 2010, Kahle et al. 2013) as shown in Study 1 (Chapter 4). Although the 
aetiology of GI symptoms involves multiple mechanisms, the neutralisation of gastric acid is 
considered a prominent factor (Turnberg et al. 1970). As shown in Study 1 (Chapter 4), gastro-
resistant capsules can lesson GI symptoms compared with drink solutions, while inducing 
comparable acid-base balance. There is however speculation as to how the site of disintegration 
may alter the bioavailability of bicarbonate, which is thought to be a factor modulating its 
ergogenic effects (Heibel et al. 2018). 
Whilst minimising the loss of bicarbonate anions in the stomach may augment blood 
[HCO3
–] (Farias de Oliveira, Saunders and Artioli, 2018), delaying absorption also decreases 
GI transit time; which in turn may reduce changes in blood bicarbonate. These considerations 
suggest that bioavailability may be complex; one factor relates to GI transit time while another 
to the degree of neutralisation. Therefore, overall bioavailability is dependent upon on the 
balance between bicarbonate losses through neutralisation and GI transit time which is 
determined by the ingestion form. While previous research has compared the effects of 
administering NaHCO3 in gelatine (Carr et al. 2011) and delayed-release capsules in 
comparison to a solution (Hilton, Leach, Sparks, et al. 2019), research has yet to compare the 
effects of different capsule ingestion forms. Consequently, little is currently known regarding 
how enteric coatings may affect GI symptoms and bicarbonate kinetics following NaHCO3 
supplementation. Furthermore, there is a notable lack of data regarding the efficacy of 
commercially available capsule formulations, despite this being a potential form of ingestion 
for athletes. 
The primary aim of the present study was to determine the optimal ingestion form to 









Fourteen trained (DePauw et al. 2013) males (age 24 ± 5 years, body mass 80.9 ± 11.5 kg, 
V̇O2peak 57.7 ± 5.3 ml∙kg–1∙min–1) volunteered for the study. All participants performed regular 
exercise training (≥ 3 d∙week-1) for at least two years and were free of GI-related disorders. 
Exclusion criteria included those with hypertension, renal impairment or following a salt-
restricted diet, and no participants were ingesting buffering agents or medications at the time 
of the study. Protocols were explained in full and questions were answered before the 
participants gave written, informed consent to participate in the study. Ethical approval was 
granted by the institutional research ethics committee. 
5.2.2 Experimental overview 
In a double-blind, placebo-controlled, randomised crossover design, participants attended the 
laboratory on five separate occasions. After an initial visit, experimental trials consisted of a 
placebo (PLA) and three NaHCO3 trials, whereby 300 mg·kg
–1 body mass NaHCO3 was 
administered in either gelatine, delayed-release or enteric-coated capsules. According to the 
manufacturer, the delayed-release capsules (DRcaps™) were embedded with a polymer barrier 
(Hypromellose) within the shell, whereas the enteric-coated capsules (Bicarbi™) were spray-
coated with the same ingredient. Experimental trials were counterbalanced (balanced Latin-
square) in the order of administration and conducted at least 48 h apart to allow for blood 
[HCO3





caffeine-containing beverages for 12 h, and strenuous exercise 24 h before each laboratory 
visit. 
During the initial visit, semi-nude body mass was measured (BOD POD®, COSMED, Italy) 
before participants performed an incremental exercise test to volitional exhaustion on an 
electromagnetically-braked cycle ergometer (Excalibur Sport, Lode, Netherlands). This 
involved a standardised warm-up (5 min at 70 W) before the workload increased by 1 W every 
2 s (30 W·min-1) until volitional exhaustion was reached. 
Experimental trials took place under standardised laboratory conditions (temperature 
20-22 °C, humidity 50 ± 5 %) and commenced at the same time of day to account for circadian 
rhythms (Reilly, 1990). Participants arrived at the laboratory after an overnight fast (~ 12 h) 
which was verbally confirmed upon arrival. Participants then ingested 300 mg·kg–1 body mass 
NaHCO3 or placebo (cornflour) which were administered in size 0 opaque (white) capsules. 
Each experimental capsule contained 650 mg NaHCO3 therefore doses were administered to 
the nearest whole capsule. Capsules were manually filled by the same individual using a 
capsule filling device (Capsule Connection LLC, USA) and checked for accuracy (Fisher, 
OHAUS™) before administration. Supplements were ingested with an equal volume (6 ml·kg–
1 body mass) of water (Evian®, France) within 5 min while the timing commenced at the start 
of ingestion (Jones et al. 2016). Given that water was permitted ad libitum post-ingestion, 
volumes were recorded on the first trial and replicated thereafter. Participants remained seated 
throughout although toilet breaks were permitted. 
5.2.3 Assessment of acid-base balance 
During each trial, the exposure-response was established by determining the time course of 
blood [HCO3
–] and pH. Fingertip capillary blood samples (95 μL) were obtained pre-ingestion 





Samples were collected in heparin-coated glass capillary tubes (Radiometer Medical Ltd, 
Denmark) using an aseptic technique and were analysed immediately (Radiometer ABL800 
BASIC, Denmark) for blood [HCO3
–] and pH. 
5.2.4 Gastrointestinal symptoms 
Symptoms of GI distress were recorded at the same time points using a 9-item questionnaire 
(Carr et al. 2011) including nausea, flatulence, stomach cramping, belching, stomach ache, 
bowel urgency, diarrhoea, vomiting and stomach bloating, as previously described. 
5.2.5 Statistical analyses 
Data were assessed for normality using standard graphical methods prior to analyses (Grafen 
and Hails, 2002). Blood [HCO3
–], pH and aggregated GI symptom scores were analysed using 
two-way (trial × time) analysis of variance (ANOVA) with repeated-measures. Where a 
significant main effect was found, Bonferroni post-hoc pair-wise comparisons were determined 
(Atkinson, 2002). One-way ANOVA with repeated measures were used to compare peak GI 
symptom scores and bicarbonate kinetic variables (Tlag, Cmax, ∆ Cmax, Tmax and AUC) between 
trials. Effect sizes were calculated using partial eta squared (ηp
2) and were described as trivial 
(<0.20 AU), small (0.20-0.49 AU), moderate (0.50-0.79 AU) or large ( 0.80 AU) as 
previously suggested (Cohen, 1988). The α-level of statistical significance was set at P < 0.05 
and values for P of “0.000” given by the statistical package were corrected to “< 0.0005” 
(Kinnear and Gray, 1995). Descriptive data are presented as mean ± SD unless stated otherwise. 







5.3.1 Gastrointestinal symptoms 
Ingestion form had a significant effect on GI symptoms (F1.4, 17.7 = 10.3, P = 0.003, ηp
2 = 0.44) 
with lower GI symptom scores shown during placebo compared to the gelatine (P = 0.011), 
delayed-release (P = 0.005) and enteric-coated (P = 0.02) trials (Figure 5.1). Enteric-coated 
capsules also resulted in significantly lower GI symptom scores compared to gelatine (4.8 ± 
1.4 AU; 95% CI [1.0-8.6 AU]; P = 0.025) but not delayed-release capsules (P = 0.211) post-
ingestion. Time had no effect on GI symptoms (F1.8, 23.8 = 2.1, P = 0.148, ηp
2 = 0.14) and there 
was no significant trial × time interaction (F2.6, 34.0 = 1.8, P = 0.180, ηp
2 = 0.12). 
 
 
Figure 5.1. Aggregated (mean ± SD) GI symptom scores following the ingestion of placebo 






The highest individual GI symptom (Table 5.1) occurred between 60 to 90 min post-
ingestion (gelatine 94 ± 58 min, delayed-release 91 ± 21 min, enteric-coated 73 ± 34 min) and 
was significantly earlier with enteric-coated than in the gelatine (P = 0.028) trial. No other 
differences were shown in the time to reach peak GI symptom scores (P > 0.05) between trials. 
In total, eleven participants experienced GI symptoms at the point of Tmax in the gelatine trial 
compared with seven and one in the delayed-release and enteric-coated trials respectively. 
 
Figure 5.2. Mean (± SD) peak GI symptoms reported following the ingestion of placebo and 
different NaHCO3 ingestion forms. Peak GI symptom refers to the highest individual symptom 





Table 5.1. Frequency and severity of GI symptoms following NaHCO3 ingestion (n = 14). The most frequent and severe GI symptoms are 
highlighted in bold. 
 Overall  Placebo  Gelatine  Delayed-release  Enteric-coated 
Symptoms % Mean ± SD  % Mean ± SD  % Mean ± SD  % Mean ± SD  % Mean ± SD 
Stomach bloating 100.0 4.4 ± 1.9  0.0 0.0 ± 0.0  92.9 3.7 ± 1.8  78.6 3.6 ± 2.2  50.0 2.9 ± 1.2 
Belching 92.9 3.5 ± 1.4  7.1 2.0 ± 0.0  85.7 3.4 ± 1.6  64.3 2.3 ± 1.4  57.1 2.3 ± 0.9 
Bowel urgency 92.9 5.9 ± 3.0  0.0 0.0 ± 0.0  85.7 5.9 ± 3.1  71.4 3.8 ± 2.3  21.4 3.3 ± 1.5 
Stomach ache 85.7 3.5 ± 2.3  14.3 1.5 ± 0.7  71.4 3.5 ± 2.6  57.1 2.2 ± 1.5  14.3 1.0 ± 0.0 
Stomach cramps 78.6 4.0 ± 2.2  0.0 0.0 ± 0.0  64.3 4.4 ± 2.3  28.6 2.1 ± 0.7  7.1 3.0 ± 0.0 
Flatulence 71.4 4.4 ± 2.7  0.0 0.0 ± 0.0  57.1 3.6 ± 2.9  28.6 3.0 ± 1.2  35.7 3.8 ± 2.2 
Diarrhoea 64.3 7.8 ± 3.1  0.0 0.0 ± 0.0  50.0 8.2 ± 3.4  42.9 6.2 ± 2.7  7.1 5.0 ± 0.0 
Nausea 57.1 3.0 ± 2.4  0.0 0.0 ± 0.0  35.7 3.6 ± 2.7  35.7 1.6 ± 1.3  7.1 4.0 ± 0.0 
Vomiting 14.3 1.0 ± 1.0  0.0 0.0 ± 0.0  7.1 1.0 ± 0.0  7.1 2.0 ± 0.0  0.0 0.0 ± 0.0 
Any 100.0 4.2 ± 0.8  14.3 1.8 ± 0.4  100.0 4.1 ± 1.0  85.7 3.0 ± 1.4  92.9 2.8 ± 1.5 






All fourteen participants experienced at least one GI symptom in the gelatine trial, 
compared to twelve participants in the delayed-release and enteric-coated trials (Table 5.2). 
Only two participants reported any GI symptoms in the placebo trial. Stomach bloating 
(100.0%), belching (92.9%) and bowel urgency (92.9%) were the most common GI symptoms 
overall, whereas diarrhoea (7.8 ± 3.1 AU) and bowel urgency (5.9 ± 3.0 AU) had the highest 
severity rating (Table 5.1). 
 
Table 5.2. Peak GI symptoms reported following different NaHCO3 ingestion forms. Symptom scores are 
displayed in parentheses. 
Participant Placebo Gelatine Delayed-release Enteric-coated 
1 No symptom (0.0) Bowel urgency (7.0) Stomach bloating (3.0) Belching (2.0) 
2 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (7.0) Belching (1.0) 
3 No symptom (0.0) Stomach bloating (4.0) Diarrhoea (5.5) Diarrhoea (5.0) 
4 No symptom (0.0) Bowel urgency (6.0) Flatulence (5.0) Bowel urgency (3.0) 
5 No symptom (0.0) Stomach cramp (6.0) Bowel urgency (2.0) Belching (3.0) 
6 Stomach ache (2.0) Diarrhoea (10.0) Stomach ache (4.5) Nausea (3.0) 
7 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (8.0) Bowel urgency (5.0) 
8 No symptom (0.0) Bowel urgency (4.0) Stomach cramp (1.2) Stomach bloating (3.0) 
9 No symptom (0.0) Diarrhoea (10.0) Stomach bloating (8.0) Flatulence (6.0) 
10 No symptom (0.0) Nausea (8.0) Diarrhoea (7.0) Belching (2.0) 
11 Belching (1.0) Belching (5.0) Bowel urgency (2.0) Belching (1.0) 
12 No symptom (0.0) Stomach bloating (4.3) No symptom (0.0) No symptom (0.0) 
13 No symptom (0.0) Diarrhoea (10.0) Diarrhoea (8.5) Flatulence (5.0) 





5.3.2 Acid-base responses 
Ingestion form had a significant effect on blood [HCO3
–] (F3.0, 39.0 = 53.6, P < 0.0005, ηp
2 = 
0.81) and pH (F3.0, 39.0 = 50.7, P < 0.0005, ηp
2 = 0.80) (Figure 5.3 and 5.4). Blood [HCO3
–] and 
pH were significantly lower with enteric-coated than with gelatine and delayed-release in the 
post-ingestion phase. In the post-ingestion period, there were significant effects on blood 
[HCO3
–] (F3.4, 44.1 = 143.8, P < 0.0005, ηp
2 = 0.92) and pH (F5.3, 68.5 = 36.3, P < 0.0005, ηp
2 = 
0.74). Blood [HCO3
–] at 110 min was significantly higher than at baseline, 20 and 40 min (P < 
0.0005). Blood pH was significantly higher at 140 min than at baseline and 20 min (P < 
0.0005). Significant trial × time interactions were shown for blood [HCO3
–] (F5.2, 67.3 = 28.9, P 
< 0.0005, ηp
2 = 0.69) and pH (F8.3, 108.3 = 6.0, P < 0.0005, ηp
2 = 0.32). Figures 5.3 and 5.4 
displays significant differences between trials at each time point. No changes in blood [HCO3
–
] or pH were shown for placebo throughout the post-ingestion phase (P > 0.05). 
 
Figure 5.3. Mean (± 95% CI) blood [HCO3
–] pre- and post-ingestion. *Significant from 






Figure 5.4 Mean (± 95% CI) blood pH pre- and post-ingestion. *Significant from gelatine trial 
(P < 0.05). †Significant from delayed-release trial (P < 0.05). 
 
Blood pH peaked at similar time points across trials (GEL 101 ± 30 min, delayed-
release 119 ± 23 min, enteric-coated 113 ± 32 min; P > 0.05), with no significant differences 
between trials. Changes in peak blood pH were similar in the gelatine (0.08 ± 0.02 AU) and 
delayed-release (0.08 ± 0.02 AU) trials, whereas changes with enteric-coated (0.06 ± 0.02) 







Figure 5.5. Individual changes in blood [HCO3
–] following ingestion of different NaHCO3 
ingestion forms. Grey area indicates 5 mmol∙L–1 increase in blood [HCO3
–]. 
 
Table 5.3. Within-trial variation in bicarbonate kinetic variables for different NaHCO3 ingestion 
forms. 
 
Gelatine  Delayed-release  Enteric-coated 
Variable Mean ± SD CV 
 
Mean ± SD CV 
 
Mean ± SD CV 
Tlag (min) 21 ± 5
b,c 24.9 30 ± 10a 34.6 31 ± 13a 41.1 
Cmax (mmol∙L
–1) 30.5 ± 1.9c 6.1 31.3 ± 1.4c 4.5 28.2 ± 0.9a,b 3.3 
∆ Cmax (mmol∙L
–1) 6.0 ± 1.3c 22.1 6.5 ± 1.2c 17.8 4.4 ± 0.5a,b 12.0 
Tmax (min) 95 ± 32
b 33.5 119 ± 24a 20.4 120 ± 35 29.2 
AUC (mmol∙min∙L–1) 688 ± 307c 44.7 741 ± 237c 32.0 343 ± 190a,b 55.5 
Notes: CV, coefficient of variation; Tlag, lag time; Cmax, peak blood bicarbonate ion concentration; 
∆ Cmax, change in peak blood bicarbonate ion concentration; Tmax, time to reach peak blood 







The present study is the first to investigate the effects of capsule ingestion form on GI 
disturbances and acid-base balance following NaHCO3 ingestion. The key finding is that 
enteric-coated NaHCO3 results in fewer and less severe GI symptoms compared to both the 
gelatine and delayed-release capsules. Furthermore, enteric-coated NaHCO3 resulted in very 
few participants experiencing GI symptoms at the point of peak blood [HCO3
–]; a time when 
exercise is likely to be scheduled for athletes using individualised ingestion strategies (Heibel 
et al. 2018). Interestingly, blood [HCO3
–] was increased above 5 mmol∙L–1 for longer with 
delayed-release NaHCO3 compared to the gelatine capsules (Figure 5.3), which may provide a 
greater ‘ergogenic window’ following supplementation (Carr, Hopkins and Gore, 2011), 
although this has yet to be confirmed. Altogether, these data suggest that enteric-coated 
capsules are more effective at attenuating GI symptoms following NaHCO3 ingestion however, 
delayed-release NaHCO3 maximises extracellular buffering capacity. 
In the present study GI symptoms were reported by 85.7% of the participants across all 
NaHCO3 ingestion trials, which is higher than some studies have previously reported (Sale et 
al. 2011, Driller et al. 2012, Saunders et al. 2014b). Stomach bloating, belching and bowel 
urgency were the most common reported GI symptoms overall and although less frequent, the 
severity of diarrhoea was particularly high (Table 5.1). As expected, GI symptoms decreased 
following delayed-release and enteric-coated NaHCO3 ingestion compared to the gelatine 
capsules, therefore suggesting that bypassing the stomach can alleviate many of the symptoms 
associated with acute bicarbonate loading (Farias de Oliveira, Saunders and Artioli, 2018). In 
gelatine trial (P < 0.05). bSignificant from delayed-release trial (P < 0.05). cSignificant from 





relation to causes of GI symptoms, these are unlikely to be due to the large number of capsules 
ingested since only minor symptoms were experienced with the placebo. Instead, GI symptoms 
can be attributed to the NaHCO3 alone, which also highlights that in some athletes, symptoms 
are likely to occur with oral delivery despite substantially fewer side-effects with gastro-
resistant capsules. Given the relationships observed for GI symptoms between ingestion forms, 
it appears that some individuals are more prone to GI disturbances than others, although the 
reasons for this are currently unclear. 
Exercise timed with peak alkalosis may optimise performance benefits (Gough et al. 
2017a), therefore it is prudent to consider which GI symptoms will occur at this timepoint. 
While all participants reported at least one GI symptom post-ingestion, only three participants 
reported GI symptoms at the point when exercise would likely commence. Of these 
participants, all were experiencing severe diarrhoea (10.0 AU) at the point of peak alkalosis, 
which may negatively affect subsequent exercise performance (Deb et al. 2018). Nevertheless, 
it is difficult to suggest which GI symptoms may adversely affect exercise performance based 
on the current data. Since very few exercise-based studies have quantified GI symptoms, it may 
be the severity that modulates the effects on performance, rather than GI symptoms per se. This 
may also explain why some studies have found GI symptoms to have deleterious effects on 
performance with NaHCO3 supplementation (Cameron et al. 2010, Saunders et al. 2014a, Deb 
et al. 2018) whereas others have not (Price and Simons, 2010, Miller et al. 2016). To elucidate 
the effects of GI disturbances on performance, future studies should look to describe the GI 
symptoms experienced immediately prior to exercise, as well as the athletes perceived 
readiness to commence. 
Blood [HCO3
–] and pH corresponded to increases typically observed with 300 mg·kg–
1 body mass NaHCO3 (Matson and Tran, 1993), however this was not observed with enteric-





with changes of ~ 4 mmol∙L–1 post-ingestion, which may hinder the effect on exercise 
performance. Bicarbonate anions are actively transported across the intestinal mucosa rather 
than passively and become saturated (Turnberg et al. 1970), which could explain why blood 
concentrations are reduced with enteric-coated NaHCO3. Furthermore, as enteric-coated 
capsules do not disintegrate until reaching the small intestine, the time available for absorption 
is decreased which may have contributed to reduced blood concentrations. Similar to previous 
work (Gough et al. 2017b), changes in blood [HCO3
–] and pH demonstrated a high degree of 
inter-individual variability following NaHCO3 ingestion (Table 5.3).  Interestingly, changes in 
blood [HCO3
–] were less variable with enteric-coated capsules which suggests that much of the 
variation derives from the degree of neutralisation in the stomach. Although blood [HCO3
–] 
was similar between gelatine and delayed-released NaHCO3, concentrations were elevated for 
longer in the delayed-release form. Similarly, more participants reached concentrations that are 
associated with performance-enhancing effects (Carr, Hopkins and Gore, 2011). Given that 
higher pre-exercise blood [HCO3
–] is associated with greater performance enhancements 
(Matson and Tran, 1993), ingestion form may alter the ergogenic potential of NaHCO3 
supplementation. 
5.5 Conclusions 
In conclusion, the ingestion of NaHCO3 in delayed-release or enteric-coated capsules 
attenuates GI disturbances following NaHCO3 ingestion. Enteric-coated NaHCO3 is optimal 
for minimising GI symptoms and may be favourable for those who report GI disturbances 
following supplementation, even in those who have tried alternative ingestion strategies. Given 
the dramatic variation in the timing of peak blood [HCO3
–] (60-180 min) across ingestion 
forms, it is recommended that athletes continue to adopt an individualised ingestion strategy. 





blood-gas analyser, whereas delayed-release and enteric-coated NaHCO3 can be ingested 90-
120 min before exercise. Given that blood buffering capacity was blunted with enteric-coated 




































Chapter 6: The Effects of Enteric-Coated NaHCO3 Supplementation on High-Intensity 








In studies 1 (Chapter 4) and 2 (Chapters 5) it was shown that the prevalence of GI symptoms 
was high (86-100%), with stomach bloating and diarrhoea being the most frequent and severe 
symptoms, respectively. Whilst enteric-coated capsules were more affective at reducing GI 
symptoms compared with delayed-release capsules, the efficacy relating to exercise 
performance has yet to be questioned. Given that increases in blood [HCO3
–] were lower with 
enteric-coated capsules, the subsequent effects on exercise performance warrants further 
investigation. 
High-intensity exercise bouts are impaired by peripheral fatigue, typically as a result of 
disturbances to intramuscular homeostasis (Thomas et al. 2014). Significant decreases in 
muscle and blood pH have been observed due to the glycolytic contribution during high-
intensity exercise (Hollidge-Horvat et al. 2000). While the mechanisms responsible for the 
decline in muscular force across the neuromuscular junction are equivocal (Fitts, 2016, 
Westerblad, 2016), reductions in muscle pH are associated with simultaneous declines in 
muscle excitability (Cairns and Lindinger, 2008), contractility (Spriet, Matsos and Peters, 
1985) and exercise performance (Raymer, 2004). Nutritional strategies that offset these 
perturbations to acid-base balance have therefore received considerable attention.  
Inducing metabolic alkalosis prior to exercise, which can be achieved by oral ingestion 
of NaHCO3, has been found to improve various performance measures (e.g. power, speed, 
time-to-completion) during single-bouts of high-intensity exercise (Matson and Tran, 1993, 
Peart et al. 2011, Lancha Junior et al. 2015). Through increases in extracellular [HCO3
–], 
NaHCO3 supplementation can augment buffering capacity (Siegler et al. 2012) and strong ion 
handling (Raymer, 2004), both of which favour high-intensity exercise performance. Although 
0.2 to 0.4 g∙kg–1 body mass NaHCO3 is generally regarded as ergogenic during high-intensity 





individuals reporting severe symptoms at the onset of exercise (Burke and Pyne, 2007, Kahle 
et al. 2013). Whilst some studies have shown that NaHCO3 can improve exercise performance 
despite GI disturbances (Price and Simons, 2010), there is evidence to suggest that symptoms 
may compromise the performance-enhancing effects of supplementation (Cameron et al. 2010, 
Saunders et al. 2014a, Deb et al. 2018). Furthermore, there are claims that athletes may be 
deterred from supplementing with NaHCO3 due to the risk of adverse side-effects during 
training and/or competition (Heibel et al. 2018).  
Whilst enteric-coated NaHCO3 can reduce GI symptoms post-ingestion as shown in 
studies 1 and 2, no study to date has investigated the effects on exercise performance. 
Therefore, it is unknown whether ingesting NaHCO3 in enteric-coated capsules alters the 
overall ergogenicity of supplementation. Furthermore, knowledge of the performance-
enhancing potential of enteric-coated NaHCO3 would help to elucidate the impact of GI 
symptoms and acid-base balance on exercise performance, as well as improve the practical 
recommendations for athletes. The aim of the present study therefore, was to determine whether 




Eleven trained male cyclists (according to DePauw et al. 2013) were recruited for the study 
(age 32 ± 12 years, body mass 81.5 ± 12.5 kg, height 1.8 ± 0.1 m, V̇O2peak 63.2 ± 4.9 ml∙kg–
1∙min–1) based upon sample size estimation. Sample size was determined a priori and revealed 
that eleven participants were required to detect changes (~ 3 s; 1.3%) in time-to-completion 
between conditions with high statistical power (α = 0.05; β = 0.20). The benchmark for change 





and non-podium position for similar cycling events (Christensen et al. 2017). All participants 
undertook regular cycling (≥ 3 d∙week–1) for at least 5 h∙week–1 and were free of GI-related 
disorders. Exclusion criteria included those with hypertension, renal impairment 
or following a salt-restricted diet, and no participants were ingesting any nutritional 
supplements or medications at the time of the study. Ethical approval was obtained by 
the institutional research ethics committee and all participants gave written informed consent 
to take part in the study. 
6.2.2 Experimental design 
In a randomised, double-blind, and crossover design, participants attended the laboratory on 
six occasions, separated by at least 48 h and at the same time of day (0900 h). During the initial 
visit, participants completed a preliminary test to determine V̇O2peak before familiarisation with 
the 4 km cycling TT. During the further two visits, individual responses to NaHCO3 ingestion 
(gelatine and enteric-coated) were established to determine subsequent ingestion timings. 
Throughout the next three visits, participants performed a maximal 4 km TT (TT) under three 
different experimental conditions that were administered in a counterbalanced order. 
Experimental trials involved the consumption of 0.3 g∙kg–1 body mass of NaHCO3 in either 
enteric-coated or gelatine capsules, or a placebo containing cornflour prior to the 4 km TT. 
Participants were instructed to abstain from alcohol and caffeine consumption for 12 h, and 
strenuous exercise 24 h before each laboratory visit. Water intake was encouraged in the 24 h 
preceding experimental testing and participants were asked to arrive at the laboratory after an 
overnight fast and well-hydrated. On arrival to the laboratory, pre-test instructions were 
confirmed verbally to limit confounding nutritional effects on exercise performance. 





the 4 km TT, whereas acid-base balance and GI symptoms were recorded immediately pre- and 
post-exercise. 
6.2.3 Preliminary testing 
Participants undertook an incremental exercise test to volitional exhaustion on an 
electromagnetically-braked cycle ergometer (Lode Excalibur Sport, Groningen, The 
Netherlands) which confirmed that V̇O2peak was > 55 ml∙kg–1∙min–1. The protocol involved a 5 
min warm-up at 70 W and a self-selected cadence (70–120 rev∙min–1), after which the workload 
increased by 1 W every 2 s (30 W·min–1) until volitional exhaustion. Breath-by-breath gases 
were measured continuously throughout using a gas analyser (Oxycon Pro™, Jaeger, 
Germany) whereas heart rate (Polar®, Kempele, Finland) and RPE were recorded each minute 
(Borg, 1973). The following criterion were used to confirm that V̇O2peak had been reached: (i) 
heart rate within 10 beats∙min–1 of age-predicted maximum; (ii) RER > 1.10 arbitrary units 
(AU); (iii) RPE > 18/20 AU (Midgley et al. 2007). After a period of recovery (30 min), 
participants performed a 4 km cycling TT to familiarise themselves with the exercise protocol. 
Individual responses to the ingestion of enteric-coated and gelatine NaHCO3 were established 
to allow exercise to be scheduled with peak bicarbonate buffering capacity. This method 
accounts for the inter-individual variability in acid-base kinetics following NaHCO3 ingestion 
(Jones et al. 2016) and differences between ingestion forms (Hilton, Leach, Hilton, et al. 2019). 
Semi-nude body mass was recorded (Bod Pod®, Cosmed, Rome, Italy) after bladder 
evacuation to determine the dose of NaHCO3. Participants then consumed 300 mg·kg
–1 body 
mass of NaHCO3 which was administered in either size 0 opaque enteric-coated (Bicarbi™, 
Nephcentric©, Arizona, USA), or gelatine (Bulk Powders™, Colchester, UK) capsules. 
Enteric-coated capsules were pre-filled by the manufacturer, whereas gelatine capsules were 





Arizona, USA), whereas enteric-coated capsules were pre-filled by the manufacturer. Given 
that each capsule contained 0.65 g of NaHCO3, supplements were administered to the nearest 
whole capsule. All supplements were checked for accuracy (Ohaus®, Fisher Scientific™, 
Pennsylvania, USA) prior to administration and were ingested with an equal volume (6 ml·kg–
1 body mass) of water (Evian®, Danone, Paris, France) within 5 min of commencing ingestion. 
Fingertip capillary blood samples (95 μL) were drawn pre-ingestion and then every 20 min for 
180 min post-ingestion, with 10 min sampling from 80 to 140 min. Fingertip capillary blood 
samples were collected in heparin-coated glass capillary tubes (Radiometer Medical Ltd, 
Copenhagen, Denmark) using an aseptic technique and analysed immediately (Radiometer 
ABL800 BASIC, Copenhagen, Denmark) for blood [HCO3
–] and pH. 
6.2.4 Experimental testing 
Upon arrival to the laboratory, participants sat resting for 20 min before a baseline (pre-
ingestion) capillary blood sample was taken. Participants then ingested either 300 mg·kg–1 
body mass of NaHCO3 administered in gelatine or enteric-coated capsules, or a placebo. The 
opaque gelatine capsules were also used in the placebo trials and an equal number of capsules 
were given to mask the experimental conditions. Pre-exercise acid-base balance was 
determined with a further blood sample, after the pre-determined time-to-reach peak blood 
[HCO3
–] had passed. All blood samples were analysed immediately for [HCO3
–] and pH, as 
well as for blood [Na+] and [K+]. 
6.2.5 Time trials 
Participants selected a preferred handlebar and saddle position which was then replicated for 
all other experimental trials. After a 5 min self-selected warm-up and 3 min rest, participants 





(Velotron Pro®, RacerMate™, Seattle, USA) from a static start. Participants were instructed 
to complete the TT as fast as possible and were free to change gears throughout, although gear 
ratios were fixed. Visual feedback of cadence, gearing and distance travelled was provided on-
screen, although participants were blinded from power output, speed and time elapsed. Strong 
verbal encouragement was given by the same individual at regular (0.5 km) intervals 
throughout and no water was provided during the TT. All TTs took place under standardised 
laboratory conditions (temperature 18-20 °C, humidity 45 ± 5%) and a fan was placed 5-m in 
front of the cycle ergometer to promote evaporative cooling. Participants undertook a 5 min 
cool-down at a self-selected workload immediately after completion of the TT. 
6.2.6 Physiological and perceptual measures 
During each TT, blood La– was measured pre- and post-exercise, and every 1-km throughout 
using a portable lactate monitor (Lactate Pro 2, Arkray, Japan). At the same time points, lower-
limb ratings of perceived exertion (RPE-L) and RPE were recorded using a 6–20 scale (Borg, 
1973), whereas perceived ratings of fatigue (ROF) were recorded on a 10-point Likert scale 
(Micklewrigtht et al. 2017). Heart rate was measured pre- and post-exercise, and every 0.5-km 
throughout the TT (Polar®, Kempele, Finland). Symptoms of GI distress were recorded 
immediately pre-exercise using an adapted GI symptom questionnaire (Carr et al. 2011) as 
previously described. Symptom terminology was explained to participants before the 
experimental trials commenced to ensure consistency in the reporting of symptoms.  
6.2.7 Statistical analyses 
Data normality was assessed using the Shapiro–Wilk test and by visual inspection of the 
normality plots (Grafen and Hails, 2002). One-way analysis of variance (ANOVA) for 





cardiovascular (heart rate), blood ([HCO3
–], pH, [La–], [Na+], [K+] and [Cl–]), perceptual (RPE, 
RPE-L and ROF) and performance (power) variables were analysed using two-way (condition 
× time) ANOVA for repeated-measures. Where a significant main effect was found, 
Bonferroni-adjusted post-hoc paired comparisons were determined (Atkinson, 2002). Effect 
sizes were reported as partial eta squared (ηp
2) for one- and two-way ANOVA, whereas 
Hedge’s g and 95% CI were calculated for paired comparisons. Effects were discussed in 
relation to the relevant literature (Thompson, 2007) and described as trivial (<0.20), small 
(0.20-0.49), moderate (0.50-0.79) or large ( 0.80) as previously suggested (Cohen, 1988). 
Statistical significance was set at P < 0.05 and values for P of “0.000” given by the statistical 
package were corrected to “< 0.0005” (Kinnear and Gray, 1995). Descriptive data are presented 
as mean ± SD throughout. Data were analysed using the Statistical Package for the Social 
Sciences version 25 software (IBM®, Chicago, USA), whereas sample size was calculated 
using GPower® version 3.1.9.2 (Faul et al. 2007). 
6.3 Results 
6.3.1 Exercise performance 
There was a significant improvement in time-to-completion (Figure 6.1) in the NaHCO3 trials 
compared with the placebo (F2.0, 20.0 = 10.6, P = 0.001, ηp
2 = 0.52). Time-to-completion was 
significantly faster with enteric-coated (mean difference = 8.6 s [−2.3%], P = 0.044, 95% CI 
[0.2, 16.9 s], g = 0.41) and gelatine (mean difference = 9.6 s [−2.6%], P = 0.004, 95% CI [3.4, 
15.9 s], g = 0.50) NaHCO3 compared with the placebo, but there was no difference between 
enteric-coated and gelatine NaHCO3 (mean difference = −1.1 s, P = 1.00, 95% CI [–5.7, 3.5 s], 
g = −0.1). Acute bicarbonate loading had a significant effect on power output (F2.0, 20.0 = 8.8, P 
= 0.002, ηp
2 = 0.47; Figure 6.1), with higher values in the gelatine trial when compared with 





> 0.05). There was significant variation in power output across the TT (F1.4, 14.1 = 12.8, P = 
0.002, ηp
2 = 0.56) with power output declining between 1 and 2 km (P = 0.001) before reaching 
a plateau (P = 0.123) at 3 km, followed by an increase towards 4 km (P = 0.026). Pacing 
strategies were similar between conditions (Figure 6.1), with no significant condition × time 
interaction (F2.6, 26.1 = 0.4, P = 0.746, ηp
2 = 0.04). No order effect on TT performance was shown 
given that neither time-to-completion nor power output differed between the first to last trial 






Figure 6.1. Mean (± SD) time-to-completion (A) and power output (B) following the ingestion 
of 300 mg·kg–1 body mass NaHCO3 in gelatine (●) or enteric-coated (○) capsules, or a placebo 
(■). Individual responses are given for time-to-completion. ✱Significant difference between 
gelatine NaHCO3 and placebo (P < 0.05). 
#Significant difference between enteric-coated 






6.3.2 Acid–base balance 
Blood [HCO3
–] was significantly higher in the NaHCO3 conditions compared with the placebo 
(F2.0, 20.0 = 23.5, P <0.0005, ηp
2 = 0.70, Figure 6.2), with no difference between enteric-coated 
and gelatine capsules (P = 1.0). Blood [HCO3
–] increased pre-exercise (P < 0.0005) followed 
by a decrease post-exercise (P < 0.0005), with a condition × time interaction (F4.0, 40.0 = 48.2, 
P < 0.0005, ηp
2 = 0.83). Pre-exercise blood [HCO3
–] was significantly higher in the enteric-
coated (3.8 ± 1.0 mmol∙L–1, P < 0.0005, 95% CI [3.0, 4.7 mmol∙L–1]) and gelatine (5.6 ± 1.5 
mmol∙L–1, P < 0.0005, 95% CI [4.3, 6.3 mmol∙L–1]) conditions compared with the placebo. 
Furthermore, blood [HCO3
–] was significantly lower with enteric-coated compared with 
gelatine capsules pre-exercise (mean difference = 1.8 mmol∙L–1, P = 0.012, 95% CI [0.4, 3.3 
mmol∙L–1). 
Blood pH was significantly higher in the NaHCO3 conditions compared with the 
placebo (F2.0, 20.0 = 14.6, P <0.0005, ηp
2 = 0.59, Figure 6.2), with no difference between enteric-
coated and gelatine capsules (P = 1.0). Blood pH increased pre-exercise (P < 0.0005) followed 
by a decrease post-exercise (P < 0.0005), with a condition × time interaction (F2.0, 19.7 = 48.2, 
P = 0.001, ηp
2 = 0.55). Pre-exercise blood pH was significantly higher in the enteric-coated 
(0.038 ± 0.016 AU, P < 0.0005, 95% CI [0.024, 0.052 AU]) and gelatine (0.074 ± 0.019 AU, 
P < 0.0005, 95% CI [0.058, 0.091 AU]) conditions compared with the placebo. Blood pH was 
also significantly lower with enteric-coated compared with gelatine capsules pre-exercise 








Figure 6.2. Mean (± SD) blood [HCO3
–] (A), pH (B), [Na+] (C) and [K+] (D) pre-ingestion, 
pre-exercise (post-ingestion) and post-exercise. ✱Significant difference between gelatine 
NaHCO3 and placebo (P < 0.05). 
#Significant difference between enteric-coated NaHCO3 and 
placebo (P < 0.05). †Significant difference between gelatine and enteric-coated NaHCO3 (P < 
0.05). 
6.3.3 Electrolyte responses 
Acute bicarbonate loading did not alter blood [Na+] (F2.0, 20.0 = 1.0, P = 0.394, ηp
2 = 0.09, Figure 
6.2), although there were significant increases shown post-exercise (F2.0, 20.0 = 20.5, P < 0.0005, 
ηp
2 = 0.67). No condition × time interaction was found for blood [Na+] (F4.0, 40.0 = 0.3, P = 
0.850, ηp
2 = 0.03). Similarly, NaHCO3 ingestion did not alter blood [K






2 = 0.02, Fig. 2d) despite significant decreases post-exercise (F2.0, 20.0 = 41.1, P < 
0.0005, ηp
2 = 0.80), with no condition × time interaction (F4.0, 40.0 = 0.6, P = 0.660, ηp



















Figure 6.3 Mean (± SD) blood [La–] (A) and heart rate (B) response during the 4 km TT 
following the ingestion of 300 mg·kg–1 body mass NaHCO3 in gelatine (●) or enteric-coated 







6.3.4 Physiological and perceptual responses 
Blood [La–] (F2.0, 20 = 7.7, P = 0.003, ηp
2 = 0.43; Fig. 3a) were significantly greater in the 
gelatine trial compared with the placebo (mean difference = 2.4 mmol∙L–1, P = 0.003, 95% CI 
[0.9, 3.8 s], g = 0.90). No further differences in lactate responses were shown between 
conditions (P > 0.05), although blood [La–] progressively increased during all TT’s (F1.4, 13.9 = 
127.3, P < 0.0005, ηp
2 = 0.93), without a condition × time interaction (F2.5, 25.2 = 2.0, P = 0.152, 
ηp
2 = 0.16). Heart rate progressively increased throughout the 4 km TT (F1.1, 10.9 = 43.8, P < 
0.0005, ηp
2 = 0.81; Figure 6.3), although no significant differences were shown between 
conditions (F2.0, 20 = 0.7, P = 0.491, ηp
2 = 0.07), nor was there a significant condition × time 
interaction (P = 0.385). Despite improvements in TT performance in both NaHCO3 conditions, 
there were no differences in neither RPE (F2.0, 20.0 = 2.2, P = 0.137, ηp
2 = 0.18), RPE-L (F2.0, 20.0 
= 0.2, P = 0.841, ηp
2 = 0.02) nor ROF (F2.0, 20.0 = 3.5, P = 0.05, ηp
2 = 0.26) between conditions, 
although there were significant increases in RPE (F3.0, 30.0 = 63.2, P < 0.0005, ηp
2 = 0.86), RPE-
L (F1.4, 14.4 = 45.2, P < 0.0005, ηp
2 = 0.82) and ROF (F1.2, 12.4 = 2.2, P < 0.0005, ηp
2 = 0.87) 
during the TT (Table 6.1). No significant condition × time interactions were shown for neither 
RPE (F6.0, 60.0 = 0.9, P = 0.524, ηp
2 = 0.08), RPE-L (F6.0, 60.0 = 0.4, P = 0.893, ηp
2 = 0.04) nor 
ROF (F6.0, 60.0 = 0.8, P = 0.583, ηp











Table 6.1. Mean (± SD) perceptual responses during the 4 km 
TT. 
 Condition 
 Placebo Gelatin Enteric 
RPE (AU) 
 
1-km 11.6 ± 1.9 11.5 ± 2.8 12.5 ± 2.0 
 
2-km 13.3 ± 2.2 12.4 ± 2.5  14.0 ± 1.7* 
 
3-km 14.8 ± 2.2* 13.8 ± 1.8 15.2 ± 2.1* 
 
4 km 16.6 ± 2.3* 16.0 ± 2.8* 16.6 ± 2.2* 
RPE-L (AU) 
 
1-km 13.5 ± 2.7 13.6 ± 2.2 13.7 ± 2.1 
 
2-km 14.7 ± 2.5 14.6 ± 2.2* 15.0 ± 1.7 
 
3-km 16.1 ± 1.9* 15.9 ± 2.0* 16.2 ± 1.6* 
 
4 km 17.3 ± 2.4 17.8 ± 1.7* 18.0 ± 2.1* 
ROF (AU) 
 
1-km 3.9 ± 1.8 3.2 ± 1.3 3.5 ± 1.1 
 
2-km 5.0 ± 1.4* 4.7 ± 0.9* 5.2 ± 1.0* 
 
3-km 5.8 ± 1.1* 5.4 ± 1.2 6.2 ± 1.3 
 
4 km 7.5 ± 1.3* 6.6 ± 1.2* 7.5 ± 1.4* 






6.3.5 Gastrointestinal symptoms 
No GI symptoms were reported pre-ingestion in all conditions. No participants reported GI 
symptoms pre-exercise with the placebo, whereas fewer participants experienced symptoms 
with enteric-coated (n = 7) compared to gelatine (n = 3) NaHCO3. Pre-exercise GI symptom 
scores were significantly higher following gelatine NaHCO3 (3.6 ± 3.9 AU) compared with 
placebo (P = 0.043), with no difference between enteric-coated NaHCO3 (1.0 ± 1.7 AU) and 
placebo (P = 0.324). Furthermore, pre-exercise GI symptoms were less severe with enteric-
coated NaHCO3 compared to gelatine at the individual level (Table 6.2), although group 
symptom scores were not significantly different (P = 0.211) between enteric-coated and 






Table 6.2. Individual GI symptom scores immediately before exercise. 
Symptoms are displayed in bold for clarity and scores are displayed in 
parentheses. 
 Condition 
 Placebo Gelatin Enteric 
Participant  
  
1 No symptom (0.0) 
No symptom (0.0) No symptom (0.0) 
2 
No symptom (0.0) Diarrhoea (10.0) No symptom (0.0) 
3 
No symptom (0.0) Stomach ache (1.3) No symptom (0.0) 
4 
No symptom (0.0) Stomach cramp (1.5) No symptom (0.0) 
5 
No symptom (0.0) No symptom (0.0) Flatulence (5.0) 
6 
No symptom (0.0) Diarrhoea (6.0) No symptom (0.0) 
7 
No symptom (0.0) Bloating (5.0) Bloating (3.0) 
8 
No symptom (0.0) No symptom (0.0) No symptom (0.0) 
9 
No symptom (0.0) Bowel urgency (5.0) No symptom (0.0) 
10 
No symptom (0.0) Diarrhoea (10.0) Bloating (2.0) 
11 
No symptom (0.0) No symptom (0.0) No symptom (0.0) 
 
6.4. Discussion 
This is the first study to investigate the effect of enteric-coated NaHCO3 supplementation on 





buffering agents. The main finding of this study was that ingesting enteric-coated NaHCO3 
prior to exercise improved (~ 2.3%) subsequent 4 km cycling TT performance among trained 
cyclists. Despite inducing a lower degree of metabolic alkalosis with enteric-coated NaHCO3 
(Figure 6.2), there were no differences in exercise performance compared with a standard 
ingestion form (i.e. gelatine capsules). Furthermore, enteric-coated NaHCO3 reduced GI 
symptoms experienced immediately before exercise compared with gelatine capsules (Table 
6.2), although subjective ratings of GI symptoms in this sample were low. When taken together, 
these data suggest that enteric-coated NaHCO3 improves high-intensity cycling performance in 
those with mild to moderate GI symptoms. However, the effects of enteric-coated NaHCO3 on 
exercise performance could be greater in those who experience more severe GI symptoms at 
the onset of exercise, although this warrants further investigation. Athletes who experience GI 
side-effects following acute bicarbonate loading may therefore benefit from enteric-coated 
NaHCO3 supplementation prior to exercise. 
Numerous studies have investigated the effects of NaHCO3 on simulated high-intensity 
TT events with equivocal outcomes (Callahan et al. 2017, Gough et al. 2018). Where some 
studies have reported performance improvements (Gough et al. 2018) others have reported no 
benefit (Callahan et al. 2017, Correia-Oliveira et al. 2017) following supplementation. This 
disparity between studies could be explained by the timing of supplementation, given that the 
current study demonstrated positive outcomes when exercise was timed with peak alkalosis. 
Studies that have reported no effect of NaHCO3 ingestion during similar exercise protocols 
have administered the supplement at a standardised time (Callahan et al. 2017; Correia-Oliveira 
et al. 2017) despite considerable variability in the time taken to reach metabolic alkalosis (Jones 
et al. 2016). Time between ingestion and the onset of exercise largely determines the degree of 
metabolic alkalosis in terms of blood [HCO3
–] and pH (Heibel et al. 2018), which in turn, may 





effect of NaHCO3 on exercise performance in the present study was mediated by the ingestion 
form, with a small to moderate effect on time-to-completion (2.3–2.6%) with gelatine and 
enteric-coated NaHCO3, respectively. The present study reported a mean 5.6 mmol∙L
–1 increase 
in blood [HCO3
–] with gelatine compared to placebo, which is lower than the 3.8 mmol∙L–1 
increase observed with the enteric-coated capsules. This finding is consistent with previous 
studies that have investigated the acid-base kinetics following NaHCO3 ingestion (Hilton, 
Leach, Hilton, et al. 2019) , which could account for the difference in effect size observed in 
the present study. Nevertheless, exercise performance still improved with enteric-coated 
NaHCO3 supplementation, which questions the 5-6 mmol∙L
–1 threshold suggested to improve 
performance (Heibel et al. 2018). Indeed, the improvements in 4 km cycling TT performance 
in the present study are similar to previous studies, despite a greater blood [HCO3
–] reported 
by others (Gough et al. 2018). While individualising the timing of supplementation may 
increase the likelihood of commencing exercise with greater blood buffering capacity, it is not 
clear that utilising an individualised strategy maximises the ergogenicity of NaHCO3 
supplementation. Given this disparity between studies, it is unlikely that timing is the only 
factor modulating the ergogenicity of NaHCO3 during high-intensity exercise. However, 
further research should look to compare the effects of an individualised and standardised 
ingestion time on subsequent performance, particularly when standardised times are based on 
existing group data. 
Given that enteric-coated NaHCO3 improves exercise performance among those with 
mild to moderate GI symptoms, the effects on exercise performance may be enhanced among 
those with more severe GI symptoms at the onset of exercise. While GI side-effects were 
significantly reduced in some individuals in the current study (Table 6.2), numerous individuals 
did not report symptoms at the onset of exercise. Although ergogenic doses (~ 0.3 g∙kg–1 body 





exercise performance. This is consistent with previous studies (Hilton, Leach, Hilton, et al. 
2019, Hilton, Leach, Sparks, et al. 2019) demonstrating the reduced incidence of GI symptoms 
at the time of peak alkalosis, despite severe symptoms at other timepoints. It is therefore 
difficult to elucidate whether GI symptoms can negate the ergogenic effects of NaHCO3 
supplementation from the current data, since the overall incidence and severity of GI symptoms 
was low. Nevertheless, GI side-effects may hinder high-intensity exercise performance or 
dampen the ergogenic effects of NaHCO3 supplementation (Saunders et al. 2014a). Further 
research should therefore examine the effects of enteric-coated NaHCO3 supplementation in 
those who typically report moderate to severe GI disturbances at the onset of exercise, as the 
effects may be greater among these individuals. 
While psychological indicators of perceived exertion and fatigue increased during 
exercise, no differences were reported between the placebo and NaHCO3 conditions (Table 
6.1), suggesting an alternative mechanism other than reductions in afferent feedback to the 
central nervous system (Siegler and Marshall, 2015). Nevertheless, this finding indicates the 
enhancements in power output were attained at a relatively similar RPE when supplementing 
with NaHCO3. Similarly, despite distinct changes in blood [Na
+] and [K+] during exercise, no 
differences were observed between NaHCO3 and placebo (Figure 6.2). Changes in these strong 
ions can impair muscle excitability (Cairns and Lindinger, 2008), therefore suggesting that 
improvements in performance were not due to ionic shifts in [Na+] and [K+] associated with 
enhanced contractility. Nevertheless, enhanced muscle contractile function cannot be 
dismissed as a potential mechanism, as altered calcium handling can improve mechanical 
efficiency (Siegler and Marshall, 2015), although this cannot be elucidated from the current 
study. Alternatively, given that pre-exercise blood [HCO3
–] and pH were greater in the 
NaHCO3 conditions compared to placebo, the performance improvements observed in the 






– are suggested to promote H+ efflux from intramuscular to extracellular 
regions through increases in monocarboxylate transporter activity, which maintains muscle pH 
during exercise (Bishop et al. 2008). Given the delayed onset of intramuscular acidosis, 
NaHCO3 promotes glycolytic enzyme activity and flux, as indicated through increases in 
muscle glycogen utilisation and lactate concentrations (Hollidge-Horvat et al. 2000). Although 
muscle pH and lactate were not measured in the current study, increases in muscle pH and 
lactate efflux have been observed during exercise following NaHCO3 supplementation (Costill 
et al. 1984). Augmenting glycolytic flux may have therefore permitted exercise at higher 
intensities and could explain the performance improvements observed in the current study. This 
would account for the greater blood [La–] observed with gelatine NaHCO3, although the 
increases observed with enteric-coated capsules did not reach significance (Figure 6.3). Given 
that monocarboxylate transporters 1- and 4 are stimulated by the intra- to extracellular [H+] 
gradient, the greater extracellular pH observed with gelatine capsules may have upregulated 
the co-transport of H+ and La– to a greater extent and could account for differences in the 
ergogenic effect size (0.3%). This may also explain why power output was greater when 
NaHCO3 was given in gelatine capsules (Figure 6.1), although this did not result in greater 
overall performance times compared to enteric-coated capsules. Therefore, the current 
evidence suggests that while pre-exercise blood [HCO3
–] does not determine the overall 
ergogenicity of NaHCO3 supplementation, the magnitude of such effects may be increased by 
a greater degree of metabolic alkalosis. 
6.5 Conclusions 
In summary, this study is the first to demonstrate that 0.3 g∙kg–1 body mass of enteric-coated 
NaHCO3 improves high-intensity exercise performance when timed with peak alkalosis. This 





capsules) can mediate the effects on exercise performance, potentially through the degree of 
induced alkalosis. In order to understand the implications of GI side-effects on exercise 
performance, further research should compare the effects of enteric-coated NaHCO3 
supplementation on exercise performance in those who experience severe symptoms 
immediately before exercise, particularly as GI disturbances may be ergolytic among these 
individuals. Furthermore, given the growing range of ingestion forms commercially available 
to athletes (e.g. solution, gelatine capsules, gastro-resistant capsules), future studies should 
compare the effects on exercise performance. Nonetheless, acute enteric-coated NaHCO3 
consumption improves 4 km TT performance and therefore, may offer an appropriate ergogenic 

































The aim of this thesis was to investigate the effects of gastro-resistant NaHCO3 
supplementation on markers of acid-base balance, GI symptoms and exercise performance. A 
summary of the outcomes reported in each experimental chapter are provided below: 
 
Study 1 (Chapter 4) 
The aim of this study was to determine whether 300 mg∙kg–1 body mass of delayed-release 
NaHCO3 could mitigate GI distress and alter acid-base balance compared with a solution. This 
study was the first randomised control trial investigating the effects of high-dose (300 mg∙kg–
1 body mass) gastro-resistant NaHCO3 in humans. Delayed-release NaHCO3 appeared to 
postpone the release of NaHCO3 and subsequently increase the time-to-reach metabolic 
alkalosis. Furthermore, delayed-release NaHCO3 mitigated the prevalence and severity of GI 
side-effects, although symptoms were still reported by some individuals. These findings are 
therefore the first to demonstrate that bypassing the stomach, at least in part, can reduce GI 
side-effects associated with acute bicarbonate loading. In addition, this study revealed that 
altering the ingestion form can affect NaHCO3 release and subsequent bicarbonate kinetics and 
acid-base balance. 
 
Study 2 (Chapter 5) 
The aim of this study was to investigate whether capsule composition affects GI side-effects 
and acid-base balance following acute NaHCO3 supplementation, potentially through altering 
the site of absorption across the GI tract. Symptoms of GI distress were lowest following 
enteric-coated NaHCO3 consumption and decreased as the gastro-resistant properties of the 
capsules increased. This demonstrates that enteric-coated NaHCO3 minimises GI symptoms 





due to supplementation. Nevertheless, [HCO3
–] availability was lowest following the 
consumption of enteric-coated NaHCO3 which could alter the ergogenicity of supplementation. 
 
Study 3 (Chapter 6) 
The aim of this study was to investigate whether enteric-coated NaHCO3 supplementation 
could improve high-intensity exercise performance during a 4 km cycling TT in trained male 
cyclists. This study was the first randomised control trial investigating the efficacy of enteric-
coated NaHCO3 consumption on exercise performance, which used an acute 300 mg∙kg
–1 body 
mass dosing protocol. Enteric-coated NaHCO3 supplementation provided a small ergogenic 
benefit, with a mean 9 s (2.3 ± 2.6%) time improvement when compared to the placebo. 
Furthermore, performance improvements were similar when NaHCO3 was administered in 
gelatine capsules, with a mean 10 s (2.6 ± 2.0%) time improvement when compared to the 
placebo. Nevertheless, ingestion form altered the magnitude of effect between performances, 
which could be mediated through pre-exercise blood [HCO3
–] and pH. 
The following sections are written to further discuss the general findings of this thesis, 
with limitations, practical implications and future directions provided[.  
7.1 Gastrointestinal symptoms 
In the experimental chapters (4, 5 and 6) NaHCO3 was generally not well tolerated given that 
most participants reported GI side-effects. In the context of sport however, athletes may be 
prepared to experience GI symptoms in the hope that NaHCO3 supplementation will improve 
exercise performance. This is likely to depend on individual factors, such as the severity of 
symptoms and the performance level of the athlete (e.g. novice to elite). As a result, 
practitioners should be aware that NaHCO3 supplementation may cause GI symptoms that 





recommended that athletes continue to monitor GI responses to this supplement outside of 
competition, such as during pre-season or training. 
7.1.1 Prevalence of gastrointestinal symptoms with sodium bicarbonate 
supplementation 
The oral administration of NaHCO3 has long been associated with acute GI side-effects (Burke 
and Pyne, 2007). Whilst GI symptoms vary between individuals, nausea, flatulence, stomach 
cramp, belching, stomach ache, bowel urgency, diarrhoea, vomiting and stomach bloating are 
among those typically reported by athletes (Miller et al. 2016). These symptoms are generally 
considered to be those of the upper GI tract (e.g. belching, nausea and vomiting) and the lower 
GI tract (e.g. flatulence, bowel urgency and diarrhoea), although the exact prevalence remains 
unclear. In Chapters 4 and 5, a high proportion (86-100%) of recreationally trained individuals 
reported GI symptoms following NaHCO3 supplementation irrespective of the ingestion form 
used, which is similar to that reported in a small group of well-trained athletes (Carr, Gore and 
Dawson, 2011). This highlights the potential widespread impact of NaHCO3 supplementation 
on GI side-effects when administering a 300 mg∙kg–1 body mass dose, which could explain 
why the use of NaHCO3 is low compared with other nutritional supplements (Knapik et al. 
2016). Nonetheless, this figure is greater to that reported in some studies using an acute loading 
protocol, with reported prevalence rates between 22-38% (McNaughton, Siegler and Midgley, 
2008, Driller et al. 2012). Variations between studies could be due to numerous factors, such 
as co-ingestion with a small carbohydrate-based meal (1.5 g∙kg–1 body mass), which have been 
shown to mitigate GI symptoms, and ingestion with a larger volume of water (14 ml∙kg–1 body 
mass) which can exacerbate symptoms (Carr et al. 2011). Methodological factors may also 
contribute to the variation in GI symptoms reported between studies, such as differences in the 





Furthermore, some studies have measured the time course of GI symptoms whereas other have 
recorded symptoms at a solitary timepoint, which makes comparison between these studies 
difficult. Longer sampling periods may also increase the incidence of GI symptoms given that 
side-effects can present up to 24 h post-ingestion (Cameron et al. 2010). Symptoms may also 
be greater when NaHCO3 is ingested over shorter (≤ 30 min) compared with longer (30-60 
min) time periods, although this warrants further investigation. 
 
7.2 Implications of gastro-resistant sodium bicarbonate 
7.2.1 Gastrointestinal symptoms 
Numerous ingestion strategies have been employed to mitigate GI side-effects associated with 
acute bicarbonate loading, including chronic (McNaughton and Thompson, 2001), multi-day 
(Mueller et al. 2013) and split-dose (Sale et al. 2011, Saunders et al. 2014b). Given that no 
study has investigated the effects of these strategies on GI side-effects in isolation, it is difficult 
to draw firm conclusions on the efficacy relating to symptomology. Nevertheless, it appears 
that adopting these protocols can still lead to severe GI symptoms in some individuals, which 
may even limit the performance-enhancing effects of supplementation (Saunders et al. 2014a). 
More importantly, these strategies may not be practical to implement which could prevent 
athletes from using NaHCO3. Athletes will not cease training in the days leading to competition 
for example, meaning that HCO3
– reserves may be used during these sessions and negate the 
benefits of chronic and multi-day supplementation. Chronic supplementation also requires 
higher doses of NaHCO3 (500 mg∙kg
–1 body mass), which results in higher sodium intakes and 
an excessive number of capsules taken. Ultimately, the efficacy of these protocols to reduce GI 
side-effects is questionable and may be difficult to implement in practice. In contrast, gastro-





side-effects (Chapters 4, 5 and 6). Ingesting this supplement 90-120 min before exercise is 
similar to current recommendations, making it easier for athletes to implement this nutritional 
strategy. 
Gastro-resistant ingestion forms mitigate GI symptoms associated with acute NaHCO3 
supplementation. In Chapter 4, the prevalence and severity of GI symptoms was lower when 
NaHCO3 was administered in delayed-release capsules than as a solution. In Chapter 5, similar 
reductions were observed with delayed-release NaHCO3 compared to supplementation in 
gelatine capsules, indicating the gastroprotective effect of minimising bicarbonate release in 
the stomach. Enteric-coated NaHCO3 were optimal for mitigating GI symptoms post-ingestion 
and demonstrates in vivo that bypassing the stomach is an efficacious model for minimising GI 
symptoms following NaHCO3 ingestion. Symptoms did not necessarily coincide with peak 
alkalosis, when exercise would be timed for those adopting an individualised strategy. This 
finding was later confirmed in Chapter 6, were few participants reported GI symptoms at the 
onset of exercise. Nonetheless, fewer individuals experienced GI symptoms with enteric-
coated NaHCO3, which may therefore benefit those who experience symptoms following 
supplementation. 
Whilst enteric-coated NaHCO3 is already commercially available to athletes, these 
findings are the first to investigate, and indeed support the use of enteric-coated NaHCO3 to 
reduce GI side-effects following acute supplementation. The use of enteric-coated NaHCO3 is 
therefore a valid strategy to attenuate side-effects associated with NaHCO3 supplementation 
commonly. Athletes should however be made aware that while enteric-coated NaHCO3 can 
reduce GI side-effects compared with other capsules, this is not consistent between individuals 
and symptoms may still be experienced at the onset of exercise. Furthermore, given that the 





reliable in their presentation. The reliability of enteric-coated NaHCO3 to attenuate GI side-
effects therefore warrants further investigation. 
 
7.2.2 Ingestion timing 
The experimental chapters of this thesis investigated the time to reach peak blood [HCO3
–] and 
pH following the ingestion of 300 mg∙kg–1 body mass NaHCO3. Figure 7.1 displays the 
collective findings from these chapters among recreationally trained (n = 26) and trained 
individuals (n = 11). 
Whilst it is typically recommended that NaHCO3 be administered between 60 and 90 
min prior to exercise (Renfree, 2007, Price and Simons, 2010, Carr et al. 2011, Siegler et al. 
2012), this work demonstrates that 33 out of 37 participants (89%) did not reach peak blood 
[HCO3
–] with at least one ingestion form during this window. Furthermore, this thesis presents 
novel data demonstrating that gastro-resistant NaHCO3 increases the time to induce metabolic 
alkalosis and reach peak blood [HCO3
–] and pH. Consequently, in order to maximise blood 
[HCO3
–] and pH, existing recommended ingestion timings are not appropriate for gastro-
resistant forms of NaHCO3. Instead, delayed-release and enteric-coated NaHCO3 should be 
consumed earlier than more conventional forms, such as gelatine capsules or solutions. Based 
on current evidence, athletes supplementing with either delayed-release or enteric-coated 
NaHCO3 can consume 120 min before exercise to maximise extracellular [HCO3








Figure 7.1. Individual time to reach peak blood [HCO3
–] (A) and pH (B) following 300 mg∙kg–






Ingestion timings appear to be highly variable between individuals (Chapters 4, 5 and 
6). Indeed, the time to reach peak blood [HCO3
–] and pH varies considerably with gastro-
resistant NaHCO3, which is similar to previous work reporting high inter-individual variation 
with gelatine capsules and solution (Jones et al. 2016, Miller et al. 2016). Furthermore, there 
appears to be greater variance in the timing of peak blood [HCO3
–] and pH with gastro-resistant 
ingestion forms (delayed-release and enteric-coated) compared with either a solution or 
gelatine capsules (Figure 7.1). While the reasons for these differences are unclear, this may be 
due to individual differences in gastric emptying or pre-ingestion diet (Davis, Hardy and Fara, 
1986) although this warrants further investigation. 
7.2.3 Bicarbonate kinetics and other acid–base responses 
Bicarbonate kinetics vary considerably between individuals following NaHCO3 
supplementation (Jones et al. 2016, Miller et al. 2016). Nevertheless, blood [HCO3
–] typically 
increased up to a maximal point in most individuals, followed by a progressive decline due to 
factors such as reduced absorption and compensatory mechanisms that maintain acid-base 
balance and homeostasis. Given that gastro-resistant capsules delay the release of NaHCO3, 
blood [HCO3
–] is typically elevated for longer compared with gelatine capsules (Chapter 5). 
This may be beneficial in the context of competition, where it may not be practical time 
exercise with peak [HCO3
–]. Furthermore, this may also provide a greater window for NaHCO3 
supplementation to enhance performance, although further research is needed. 
In Chapters 5 and 6, the increase in blood [HCO3
–] were blunted with enteric-coated 
NaHCO3. There are numerous potential reasons for the lower increases observed with enteric-
coated compared with gelatine capsules, despite administering the same dose. While the same 





capsule, which reduces the time available for absorption (Barbosa, Conway and Merchant, 
2017). Another plausible explanation could be due to differences in bicarbonate absorption 
across the GI tract. Mechanisms responsible for the absorption of bicarbonate vary between the 
gastric and intestinal compartments, with a shift from passive to active transport (Turnberg et 
al. 1970). Furthermore, there is some evidence (Turnberg et al. 1970) to suggest that 
bicarbonate absorption across the intestine is rate limited, meaning that further absorption may 
not take place irrespective of higher intestinal concentrations of bicarbonate. Although 
bypassing the stomach may be an efficacious model for minimising GI symptoms following 
NaHCO3 supplementation, this may not maximise concentrations in the extracellular 
compartments. Nevertheless, Chapter 6 demonstrates that higher blood [HCO3
–] do not 
necessitate greater improvements in high-intensity exercise performance.  
 
7.2.4 Efficacy of enteric-coated sodium bicarbonate to improve exercise performance 
Given that enteric-coated NaHCO3 was most effective at attenuating GI symptoms (Chapter 5) 
the efficacy relating to exercise performance was examined (Chapter 6). Enteric-coated 
NaHCO3 supplementation was found to improve 4 km TT performance by 2.3 ± 2.6% among 
trained cyclists. Fewer individuals reported GI symptoms at the onset of exercise with enteric-
coated NaHCO3, although the overall severity was similar compared with standard gelatine 
capsules. Furthermore, enteric-coated NaHCO3 prevented GI symptoms entirely in some 
individuals, which highlights the potential benefits of this ingestion strategy. Interestingly, 
increases in blood [HCO3
–] were lower when NaHCO3 was administered in enteric-coated 
compared with gelatine capsules, which supports earlier observations from Chapter 5. Despite 
lowering the bioavailability of circulating [HCO3
–], enteric-coated NaHCO3 demonstrated 





compared with gelatine capsules. This finding suggests that higher blood [HCO3
–] may increase 
the magnitude of performance-enhancing effects, rather than determine the overall 
ergogenicity. Enteric-coated NaHCO3 supplementation can therefore be considered a valid 
strategy to improve high-intensity exercise performance. 
 
7.3 Limitations 
A limitation of each study in this thesis is that a sodium-matched placebo was not used as an 
alternative to cornflour, such as sodium chloride. Given that sodium ingestion can lead to GI 
disturbances (Gisolfi, 1990), reductions in the prevalence and severity of symptoms may be at 
least partly attributable to alterations in the release of sodium ions. Nevertheless, the 
neutralisation of gastric acid is considered the overarching factor contributing to GI symptoms 
based on previous observations (Gough et al. 2017a, 2018). There are however no currently 
available ways of ingesting sodium without concomitantly disturbing acid-base balance. 
Sodium chloride, for example, can decrease blood [HCO3
–] due to altered shifts in [Cl–] 
handling, which may exaggerate the ergogenic effects of NaHCO3 supplementation (Van 
Montfoort et al. 2004). 
A further limitation of each study in this thesis is that the reliability of acid-base 
responses following NaHCO3 supplementation was not determined. Although blood [HCO3
–] 
and pH demonstrate good to excellent test-retest reliability with a solution (Gough et al. 2017a), 
it is unclear whether acid-base responses are reproducible with capsules. Given that capsules 
are emptied slowly from the stomach and demonstrate greater variation in gastric emptying 
(Davis et al. 1986), it is plausible to suggest that the observed acid-base responses and GI 





retest reliability of acid-base responses and GI symptoms with different NaHCO3 ingestion 
forms, preferably using a randomised crossover design. 
Another potential limitation of the current thesis is that all participants were fasted (~12 
h), which may not replicate the digestive state of athletes in practice. Previously, the presence 
of food in the stomach increased gastric emptying, with even a light breakfast delaying 
emptying (Davis et al. 1986). While a fasted state controls for the greater variability in gastric 
emptying after food intake, it is plausible to suggest that acid-base responses and GI symptoms 
may be affected by digestive state. As such, digestive state should be considered as a potential 
confounding factor that requires greater control during future studies. Given that gastro-
resistant capsules delay the release of NaHCO3, it would be prudent to increase the time (> 3 
h) over which acid-base balance and GI symptoms are monitored, particularly in the fed state. 
7.4 Future directions 
Ingestion form has been shown to have important relevance following NaHCO3 
supplementation. Acid-base responses, GI symptoms and exercise performance are all affected 
by ingestion form, which has often been overlooked in previous studies. This thesis therefore 
raises several pertinent questions. Firstly, does the ingestion of NaHCO3 as a solution or 
encased in gelatine capsules alter acid-base responses and exercise performance? If so, 
previous research that directly compares studies using either solutions or gelatin capsules as 
equivalent forms of supplementation should be viewed more critically. This could also be 
added as a factor when performing future meta-analyses to highlight any potential differences 
between the ingestion forms. Secondly, a study that directly compares the effects of 
encapsulation alone on acid-base responses, GI symptoms and exercise performance is also 
warranted. This will help to elucidate the impact that ingesting as a beverage or consuming in 





The association between enteric-coatings, acid-base responses and GI symptoms 
following NaHCO3 also poses new questions. Firstly, which enteric formulation optimises the 
release of NaHCO3 in the small intestine? It appears that different enteric coatings breakdown 
at different stages across the GI tract, although it is unclear which factor (type of coating, 
percentage of coating etc.) optimises the uptake of bicarbonate following NaHCO3 
supplementation. Secondly, it is unclear whether ingesting NaHCO3 as enteric-coated tablets 
or capsules would affect the important factors relating to supplementation, such as the timing 
of ingestion. Simple factors such as the size of the capsule or tablet may influence palatability, 
acid-base responses and GI symptoms and should not be overlooked. This will be particularly 
important as more commercially available forms of NaHCO3 are made available to athletes. 
Finally, whilst GI symptoms may be unpleasant for athletes and may also reduce subsequent 
exercise performance, no study has investigated the acute and chronic effects of NaHCO3 
supplementation on markers of gut damage. This is a pertinent question given that GI 
symptoms may have additional consequences on gut health and could potentially impact the 
health of the athlete. 
7.5 Conclusions and implications 
The outcomes reported in this thesis, as well as the prior literature (Carr, Gore and Dawson, 
2011), highlight the high prevalence of GI side-effects with NaHCO3 supplementation. This 
could indicate why the use of NaHCO3 is low compared with other nutritional ergogenic aids 
(Knapik et al. 2016) and emphasises the need for alternative ingestion strategies. Whilst 
existing ingestion strategies, including split- and reduced-dose (e.g. 200 mg∙kg–1 body mass) 
protocols can mitigate GI symptoms, the efficacy relating to exercise performance appears to 
be less robust. Furthermore, there is little consensus as to how these strategies should be 





(e.g. 4 h ingestion period). Alternatively, bypassing the stomach presents a novel way to 
attenuate GI symptoms following NaHCO3 ingestion, as has been previously suggested (Farias 
de Oliveira, Saunders and Artioli, 2018). The current thesis presents the first empirical 
evidence to suggest that minimising the neutralisation of gastric acid appears to be at least 
partly achievable using gastro-resistant forms of NaHCO3 (i.e. delayed-release and enteric-
coated capsules). Based on the data presented in Chapter 5, enteric-coated NaHCO3 minimises 
GI side-effects when using an acute loading protocol; a strategy commonly used amongst 
athletes. While enteric-coated NaHCO3 can reduce bicarbonate bioavailability post-ingestion, 
this does not necessarily negate the performance-enhancing effects of supplementation. Indeed, 
the findings of Chapter 6 demonstrate that supplementing with 300 mg∙kg–1 body mass enteric-
coated NaHCO3 can improve performance (~ 2.3%) during a single-bout of high-intensity 
exercise. 
Taken together, the outcomes reported in this thesis demonstrate that enteric-coated 
NaHCO3 is a valid strategy to mitigate GI symptoms and enhance high-intensity exercise 
performance. However, given that gastro-resistant NaHCO3 is an emerging ingestion strategy, 
there is currently less available evidence related to improving exercise performance compared 
with other ingestion forms. Furthermore, gastro-resistant NaHCO3 is generally more expensive 
and less commercially available than existing ingestion forms. Based upon these reasons, it is 
suggested that gastro-resistant NaHCO3 is not a replacement for more conventional ingestion 
forms (or strategies) but should be viewed as an alternate strategy to reduce GI side-effects 
among athletes. It is therefore suggested that gastro-resistant NaHCO3 should only be 
considered among those who report GI side-effects that are not tolerable, despite using existing 










• It is recommended that athletes continue to monitor GI responses to NaHCO3 
supplementation outside of competition, such as during pre-season or training. 
• Athletes supplementing with either solution or gelatine NaHCO3 can consume 60-90 
min before exercise to maximise blood [HCO3
–]. 
• Athletes supplementing with either delayed-release or enteric-coated NaHCO3 can 
consume 120 min before exercise to maximise blood [HCO3
–]. 
• Delayed-release and enteric-coated NaHCO3 can be used to reduce the risk and 
severity of GI side-effects following supplementation. 
• Enteric-coated NaHCO3 supplementation (300 mg·kg–1 body mass) can be used to 
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